Abstract: The low-density-lipoprotein receptors represent a family of pleiotropic cell surface receptors involved in lipid homeostasis, cell migration, proliferation and differentiation. The family shares common structural features but also has significant differences mainly due to tissue-specific interactors and to peculiar proteolytic processing. Among the receptors in the family, recent studies place low-density lipoprotein receptor-related protein 8 (LRP8) at the center of both neurodegenerative and cancer-related pathways. From one side, its overexpression has been highlighted in many types of cancer including breast, gastric, prostate, lung and melanoma; from the other side, LRP8 has a potential role in neurodegeneration as apolipoprotein E (ApoE) and reelin receptor, which are, respectively, the major risk factor for developing Alzheimer’s disease (AD) and the main driver of neuronal migration, and as a γ-secretase substrate, the main enzyme responsible for amyloid formation in AD. The present review analyzes the contributions of LDL receptors, specifically of LRP8, in both cancer and neurodegeneration, pointing out that depending on various interactions and peculiar processing, the receptor can contribute to both proliferative and neurodegenerative processes.

Keywords: LRP8; cancer; Alzheimer’s disease; apolipoprotein; LDL receptor family

1. Introduction

Cancer and neurodegeneration represent two age-related conditions that share common biochemical features, and it is not clear what triggers can lead to one or the other condition through apparently common routes and pathways [1–3]. It is well-known that the activation and deregulation of the cell cycle may lead to cell death in neurons and to uncontrolled proliferation in malignant cells; however, there is still a gap in the understanding of the precise molecular processes involved in both disorders; unraveling them represents an important opportunity to identify prognostic markers and to achieve therapeutic progress in both pathological conditions.

The low-density-lipoprotein receptors (LDLRs) represent a family of cell surface receptors originally linked to lipoprotein and lipid trafficking and, more recently, considered pivotal regulators of signal transduction pathways for cell proliferation, migration and differentiation [4]. Recent growing evidence has also highlighted their associations with neurodegenerative disorders and cancer due to the modulation of specific molecular pathways related to neuronal cell death and, in parallel, to cell proliferation, cell cycle activation and metastatic invasion [5–9].
2. LDLR Family

Listed in the order of their discovery, the main members of the LDLR family are: LDLR; LDLR-related protein (LRP, LRP1); Megalin (LRP-2, originally called gp330); very low-density lipoprotein (VLDL) receptor (VLDLR; in chicken termed LR8); LR11 (also named SorLA); apolipoprotein E (ApoE) receptor type 2 (LRP8, LRP-8) [4]; LRP-3, -4, -5, and -6, and LR32 (also termed LRP1B).

The structure of the LDL receptors, described in Figure 1, contains five common functional regions: a N-terminal ligand-binding domain with a variable number of LDLR type A (LA) repeats, an epidermal growth factor precursor homology (EGFP) domain composed of EGF-repeats (cysteine-rich class B repeats) and a YWTD (Tyr–Trp–Thr–Asp)/β-propeller domain, an O-linked sugar domain, a transmembrane domain and a cytoplasmic domain containing at least one NPxY (Asn-Pro-Xaa-Tyr) motif [10–12]. SorLA has two additional domains: the fibronectin type III (FNIII) domain and the vacuolar protein sorting 10 (VPS10) homology domain. In addition to the LDLR members, the NPXY motif is found in a subset of cell surface proteins well-known to be involved in cell proliferation and cancer including APP [13], growth factor receptors [14] and integrins [15].

Figure 1. The domain structure of the LDL family members: differences and similarities. LDLR, VLDLR, and LRP8 are made of seven LA repeats in the ligand-binding domain, three EGF-like domains, and one YWTD β-propeller. LRP1 and LRP2 have the largest extracellular domains, each with eight YWTD β-propellers spaced by EGF and LA repeats. LRP4, LRP5 and LRP6 carry high sequence homology to a region within LRP1 with YWTD β-repeats going three through six. SorLA has two additional domains: the FNIII domain and the VPS10 domain. Regarding the NPxY motif, VLDLR, LRP8 and LR11/SorLA-1A have a single copy, whereas LRP1 and LRP1B contain two copies and LRP2/Megalin three copies. No NPXY is present in LRP5 and LRP6. Domains are not drawn to scale.
The LDLR family participates in a wide range of physiological processes in different organs, tissues and cell types [4]. They are mainly known for binding and internalizing several extracellular ligands, including lipoproteins, exotoxins and lipid-carrier complexes, as well as for mediating signaling responses as a result of changes in the extracellular environment. The presence of the NpXy motif in the cytoplasmic domain represents an intracellular binding site for many adaptor proteins such as the mammalian Disabled-1 (mDab-1), mDab-2, FE65, JNK-interacting protein JIP-1 and JIP-2, PSD-95, CAPON, and SEMCAP-1 [16–18]; many of these contain in their structure at least one of the three frequently found interaction domains such as phosphotyrosine binding (PTB), PDZ or SH2-SH3 domains or ankryrin repeats.

A functional peculiarity of the LDL receptors, especially LRP8, is their double functional role in neurodegeneration and cancer, the main focus of this review, as summarized in Table 1.

2.1. LDLR

The low-density lipoprotein receptor (LDLR) is the prototype of a classical endocytosis receptor that mediates the uptake of ligands and is broadly expressed on multiple cell types in various tissues. In the CNS, the LDLR plays an important role in regulating the homeostasis of cholesterol in the blood and also within tissues and cells [19]. The main well-known LDLR ligand is represented by apolipoprotein E (ApoE), a 34 kDa soluble protein that is a main component of lipoproteins in plasma and a secreted glycoprotein of 34 kDa that acts as a cholesterol carrier and signaling molecule. Through its interaction with LDLR, ApoE plays a critical role in peripheral cholesterol metabolism [20] and also in cholesterol transport into the central nervous system (CNS) [21,22]. LDLR is the only member of this receptor family to demonstrate an apoE isoform-specific binding affinity (E4 > E3 >> E2). Evidence suggests that a functional interaction between ApoE and LDLR influences the risk of cardiovascular disease (CVD) and AD [23]. The apoE–LDLR interaction may also play a more direct role through the modulation of amyloid clearance and/or deposition. Several intriguing studies have shed some light on the potential pathophysiological pathways by which LDLR may contribute to AD. In cell culture, overexpression of the amyloid precursor protein (APP) led to the increased expression of LDLR and altered receptor localization [24]. Varying results in amyloid deposition have been shown in AD mouse models lacking the LDLR, with one study showing that amyloid deposition was enhanced on a LDLR null background [25], while in another study, LDLR deficiency had no effect on brain amyloid-β peptides (Aβ) levels [26].

Kim et al., showed that LDLR over-expression reduced brain ApoE levels and amyloid β aggregation [27], while further work from the same laboratory showed that LDLR over-expression in the brain increased the rate of brain-to-blood clearance of both exogenously administered and endogenous Aβ [28]. These studies, in which LDLR over-expression increases Aβ clearance, point to the upregulation of LDLR in the brain as a potential therapeutic strategy for AD.

Considering the vital role of the LDL/LDLR routine in regulating blood and intracellular cholesterol homeostasis, several studies have focused on the function of LDLR in cancer progression. Chen et al., have demonstrated that the reduced expression of LDLR in hepatocellular carcinoma cells impairs LDL uptake but promotes proliferation and metastasis in vitro and in vivo by activating MEK/ERK [29].

2.2. LRP1

LRP1 represents a key receptor in maintaining lipid metabolism. The expression of LRP1 is ubiquitous, and its upregulation has been reported in numerous human diseases. In addition to its function as a scavenger receptor for various ligands, LRP1 transduces multiple intracellular signal pathways including mitogen-activated protein kinase (MAPK), Akt, Rho and the integrin signaling pathway. LRP1 signaling plays an important role in the regulation of diverse cellular processes, such as cell proliferation, survival, motility,
differentiation and transdifferentiation, and thus, it participates in the pathogenesis of organ dysfunction and injury [30]. LRP1 is widely expressed throughout the CNS, where it modulates neuronal survival, neurite outgrowth, regeneration and calcium signaling through different ligands and cell-specific mechanisms. Indeed, LRP1 recognizes and is involved in the endocytosis of more than 40 different ligands including ApoE, APP and Aβ [31–33]. Depending on its binding to different ApoE isoforms, LRP1 is involved in calcium-related cellular processes such as increased resting calcium, calcium response to N-methyl-D-aspartate (NMDA) and neurotoxicity [34]. Moreover, LRP1 binding to lipoprotein particles containing ApoE 3/4 protects against apoptosis upon the activation of protein kinase Cδ (PKCδ) and the inactivation of glycogen synthase kinase-3β (GSK3β), with a greater effect due to lipoproteins with ApoE4 than those with ApoE3 [35]. The majority of research examining LRP1 function in the brain has focused on APP trafficking [36,37], Aβ clearance from the brain parenchyma [38] and blood–brain barrier permeability [39]. Studies on knockout mouse models have shown that LRP1 deficiency is lethal early in development [40], whereas mice lacking LRP1 exhibit severe motor and behavioral abnormalities, hyperactivity, age-dependent dendritic spine degeneration, synapse loss, neuroinflammation, memory loss and eventual neurodegeneration [41,42].

In addition to its role in neuronal-related physiological processes, an additional role in cancer development has been associated with LRP1. In particular in human glioblastoma U87 cells, LRP1 promotes cellular migration and invasion by inducing the expression of the matrix metalloproteinase-2 (MMP-2) and MMP-9 [43]. Moreover, in U87 cells, Song et al., have proposed that phosphorylated ERK is a potential mediator of LRP1-regulated MMP expression. An additional piece to this puzzle has been provided by Fayard et al., suggesting that the serine protease inhibitor serpin PN-1 is a ligand of LRP1 that activates ERK and stimulates, in turn, MMP-9 expression in breast tumor cell lines [44]. Supporting this hypothesis, an analysis of 126 breast cancer patients revealed that those patients whose breast tumors had elevated PN-1 levels had significantly higher probabilities of developing lung metastasis, but not metastasis to other sites, on relapse. Finally, it has been found that in Her-2/neu and triple-negative breast cancer (TNBC), there is an increased expression of LRP1 that is linked to neoplastic aggressiveness due to high histological grade, elevated mitotic index, Ki67 > 20% and tumor recurrence, while in endometrial carcinoma (EC), the increased expression of LRP1 is associated with p53 alterations and p16 protein overexpression [45].

2.3. LRP2/Megalin

LRP2 is a multiligand receptor mostly localized in the epithelial cells of the renal tubules [46] and the choroid plexus [47], as well as in the lateral ventricles [48] and in different CNS cells ranging from oligodendrocytes, retinal ganglion cells, cerebellar granule neurons and astrocytes to hippocampal neurons [49]. In the CNS, LRP2 modulates neuronal survival and regeneration [50] as well as learning- and memory-related physiological mechanisms such as neurite outgrowth and synaptic plasticity [49]. LRP2 neurotrophic activity is performed through its binding with Transthyretin [51], while its neurite outgrowth function seems associated with metallothionines [52] and the APP/Fe65 pathway [53]. In the blood–brain barrier, LRP2 plays a central role in the clearance/entrance of many proteins from the brain/cerebrospinal fluid, including Aβ, insulin, insulin-like growth factor (IGF)-I and ApoE. Together with LRP8, LRP2 is also known to transport selenium, which is transported in the form of the selenocysteine-enriched selenoprotein P1 (Sepp1) to target tissues, where it constitutes the active center of glutathione peroxidase, thioredoxin reductase and deiodinases. In the kidney, proximal tubule epithelial cells highly express LRP2, indicating its physiological role in the reabsorption of Sepp1. This function is confirmed by studies on LRP2-mutant mice displaying urinary selenium loss, which correlates with Sepp1 excretion in their urine and reduced selenium and glutathione peroxidase activity in the brain [54].

LRP2 genetic alterations have also been associated with pathological conditions. In particular, some LRP2 mutations lead to the protein loss of function, underlying an autosoma-
mal recessive disorder, Donnai–Barrow syndrome, characterized by several CNS functional defects [55]. Other genetic studies have associated a polymorphism located in the LRP2 promoter with AD risk, regardless of the ApoE genotype [56], as well as some LRP2 germ-line polymorphisms with increased risk of prostate cancer recurrence [57]. Moreover, somatic LRP2 mutations have been identified in gastric cancer [58]. In support of LRP2’s role in cancer, Andersen et al., have reported that LRP2 is more frequently expressed among malignant melanoma samples compared with benign counterparts and that the proliferation and survival rates of cultured LRP2-expressing melanoma cells decrease upon the siRNA-mediated knockdown of LRP2 [7].

2.4. VLDLR

VLDLR is highly expressed in adipose tissue, heart and skeletal muscle and is mainly known for the following roles: uptake of VLDL-derived lipids, enhancement of lipoprotein lipase activity and mediation of the Reelin-related pathway, together with LRP8 [59]. Reelin binding to VLDLR/LRP8 receptors activates intracellular Src family kinases (SFKs), which in turn phosphorylate the adaptor protein Disabled-1 (Dab1) in specific tyrosine residues. Although the activation of the Reelin pathway through VLDLR and LRP8 is well-known to mediate the development of the central nervous system, studies have highlighted differences between the two receptors in terms of splicing, localization, interactors and trafficking, leading to unique functions separate from the overlapping ones. In particular, the Pafah1b complex mediates the downstream effects of VLDLR on neuronal migration, but it is not necessary for the function of LRP8 [60].

In addition to its roles in neuronal physiological processes, studies have highlighted the role of VLDLR in cancer. Indeed, Lei He et al., have shown that VLDLR promotes cell proliferation and migration in adenocarcinoma SGC7901 cells via beta-catenin/TCF signaling [8], and Lei He et al., have correlated VLDLR II expression with lymph node and distant metastasis in gastric and breast cancer patients [61].

2.5. LRP4

Although it is mainly expressed in bone, where it regulates bone formation by inhibiting sclerostin in Wnt1/β-catenin signaling [62], LRP4 is also found in astrocytes of the prefrontal cortex and hippocampus, regions particularly vulnerable to AD [63]. Studies of the genetic deletion of the Lrp4 gene in 5xFAD male mice, an AD mouse model, have shown increased levels of Aβ plaques and decreased neurotransmission and cognition, supporting a link between LRP4 loss and AD [64]. In the brain, LRP4 plays roles in synaptic transmission, long-term potentiation (LTP), cognitive function [65] and adult hippocampal neurogenesis [66]. Through its ligand agrin, LRP4 regulates the formation and maintenance of the neuromuscular junction [67,68]. In particular, the agrin–Lrp4 interaction increases its binding with MuSK, which is activated and thus activates the kinase that via Dok7 and rapsyn mediates AChR clustering [69]. In addition to AD, LRP4 has been associated with cancer. In papillary thyroid cancer, LRP4 has been reported to be significantly overexpressed in both tissues and related cell lines (TPC1, BCPAP and KTC-1) in comparison with controls, likely playing a role in proliferation, migration and invasion by inducing phosphoinositide 3-kinases (PI3K)/AKT mediated epithelial–mesenchimal transition (EMT) [70]. LRP4 overexpression has also been observed in gastric cancer tissues, where it correlates with malignant proliferating clinical features, while in gastric cancer cells (MKN45, MGc803, BGC823 and AGS), LRP4 activates the PI3K/AKT under regulation of miR-140-5p [71].

2.6. LR11/SorLA

SorLA is highly enriched in the brain. As LRP1, SorLA interacts with APP, influencing its trafficking and regulating Aβ levels [72,73]. Indeed, SorLA represents one of the major cellular players contributing to abnormal APP processing and enhanced Aβ formation. In particular, SorLA acts as a retention factor for APP in trans-Golgi compartments/trans-
Golgi network, with GGA and PACS-1 adaptor proteins involved in protein transport to and from the trans-Golgi network, preventing the release of the precursor into regular processing pathways [74]. Interestingly, a peculiar alternative splicing of SORL1, induced by a non-coding RNA, is associated with the impaired processing of APP and Aβ formation [75]. A consistent loss of SorLA is observed in AD brains, particularly in vulnerable regions [76], and variants in the SORL1 gene encoding SorLA have been associated with AD risk, adding considerable support to the hypothesis that SorLA is genetically linked to AD pathogenesis [77]. However, SorLA represents another LDLR whose overexpression is linked to cancer, and in particular, it has been observed in HER2-driven cancer cell lines where the receptor regulates endosomal trafficking and oncogenic fitness of HER2 [78]. SorLA and its released soluble form are also strongly elevated in acute leukemia. Remarkably, the increased levels of soluble SorLA level were reduced in patients who achieved complete remission [79,80].

2.7. LRP5/6

LRP5 and LRP6 are two LDL receptors with amino acid sequences with 71% identity [81]. Their extracellular domains are responsible for binding Wnt ligands and their inhibitors, such as Dickkopf-related protein 1 (DKK1) and sclerostin [82]; indeed, LRP5 and LRP6 are the key players that the Wnt pathway together with the Frizzled receptors [83–85]. In particular, Wnt ligands signal through at least three different pathways: the canonical or Wnt/β-catenin pathway and the two noncanonical Wnt/JNK and Wnt/Ca2+ pathways. In the canonical pathway, the Wnt-Fzd-LRP5/6 leads to a downregulation of glycogen synthase kinase-3 (GSK-3) activity that in turn increases β-catenin levels in the cytosol, thereby facilitating its translocation to the nucleus. At the nuclear level, β-catenin forms complexes with members of the Tcf/Lef class of DNA-binding proteins modulating transcriptional activity of target promoters [86,87]. The Wnt-Fzd-LRP5/6 interaction leads to the inhibition of the axin degradosome destruction complex that is recruited to the plasma membrane, helping the interaction between LRP5/6 and axin. When LRP5/6 is phosphorylated at specific amino acidic residues (Ser1490, Thr1530, Thr1572, Ser1590, Ser1607), it acts as a direct competitive inhibitor of GSK3. The Wnt signaling, most probably through LRP5 and LRP6, can also directly activate the mammalian target of rapamycin (mTOR) pathway by decreasing GSK-3-mediated activation of the TSC2/TSC1 complex. The activation of mTOR signaling promotes cell growth in addition to representing a vital regulator of autophagy [88].

LRP5 and LRP6 receptors are expressed differently in various tissues and organs. In humans, LRP5 expression level is the highest in liver, while substantial level of expression is also observed in pancreas, prostate, placenta and small intestine. The expression level of this receptor in brain and peripheral leukocytes is very low [89]. Human LRP6 expression is highest in the ovary, with significant levels in the heart, brain, placenta, lung, kidney, pancreas, spleen and testis. The expression of LRP6 is very low in peripheral blood leukocytes, thymus and small intestine [81].

LRP5 and LRP6 have been shown to play important roles in a broad panel of cancers. This is supported by the fact that the main pathway activated by both receptors is the Wnt/β-catenin pathway, which represents a pleiotropic signal involved in cell growth, cell proliferation and polarity, cell differentiation and tissue development [90,91] with a potential link to several diseases including cancer [92–94].

LRP5 has been reported to be involved in mediating Wnt/β-catenin signaling in skeletal metastasis prostate cancer (PC) due to the increased levels of Wnt-1 and β-catenin proteins in both PC cell lines and primary specimens [95]. The presence of LRP5 has also been linked significantly with tumor metastasis such as the chondroblastic subtype of osteosarcoma [96].

LRP6 overexpression, observed in many types of cancer and malignant tissues, leads to an abnormal Wnt pathway that is linked to tumorigenesis [97]. In humans, some LRP6 single-nucleotide polymorphisms (SNPs) and mutations in the LRP6 gene have been as-
sociated with increased or decreased risk of cancer development [98]. For example, an LRP6 variant (rs6488507) in non-small-cell lung cancer (NSCLC) patients is linked to an increase in the risk of NSCLC in tobacco smokers [99]. Moreover, the overexpression of LRP6 has been documented in breast cancer [97], hepatocellular carcinoma [100], colorectal cancer [101] and pancreatic ductal adenocarcinoma (PDAC) KRAS-dependent pancreatic cancer [102]. Consistent with these observations, a reduction of LRP6 expression and/or activity inhibits cancer cell proliferation and delays tumor growth in vivo [98,103]. Although mainly known as a co-receptor of the Wnt signaling pathway and therefore related to proliferative cellular pathways, some studies have described a connection of LRP6 to neurodegeneration. The LRP6-mediated Wnt signaling pathway is, in fact, compromised in AD brains, and its deficiency in an AD mouse model exacerabates amyloid pathology, synapse loss and Aβ toxicity, synergistically accelerating AD progression [104].

2.8. LRP1B

LRP1B is closely related to LRP1 due to their overlapping structural features and thus have shared ligands such as complexes of urokinase plasminogen activator, plasminogen activator inhibitor type-1 and receptor-associated protein (RAP) [105]. Both uPA and PAI-1 are key components of the uPA system, one of the major extracellular matrix-degrading proteinase systems playing a central role in cancer invasion and metastasis as well as other physiological and pathological processes involved in tissue remodeling [106]. LRP1B ligands link the receptor to altered cellular invasion/metastasis and support the correlations observed between LRP1B genetic and epigenetic alterations and many types of cancer [107–109], including urothelial malignancies [110], esophageal squamous cell carcinomas [111], gliomas, cervical adenocarcinomas, B-cell lymphomas [112], leukemias [113] and primary pulmonary adenocarcinomas [114]. In particular, its inactivation in 40% of NSCLC cell lines caused this receptor to initially be named LRP-deleted in tumors (LRP-DIT) [115]. Despite its structural link to LRP1, however, LRP1B differs from LRP1 in terms of tissue expression, localizing mainly in the brain (cortex, hippocampus and cerebellum in neurons, activated astrocytes and microglia), thyroid and salivary gland [105,116,117]. Its wide expression in the brain may suggest a yet-unclear CNS-related biological function, in part supported by its link to Aβ generation. In fact, Cam et al., have shown that LRP1B decreases APP internalization, thus reducing Aβ generation in a framework of anti-amyloid activity [118].

Table 1. CNS/neurodegeneration and the cancer-related roles of the LDL receptors. The table summarizes roles and relative molecular pathways of all LDLR (except LRP8, which is discussed later in detail) in CNS/neurodegeneration and cancer.

| LDLR Family Members | CNS Roles/Neurodegeneration | Molecular Pathway | Refs. | Cancer Related Roles | Molecular Pathway | Refs. |
|---------------------|-----------------------------|------------------|-------|---------------------|------------------|-------|
| LDLR                | Modulation of amyloid clearance and/or deposition | ApoE interaction | [25,27,28] | Downregulation of cell proliferation and metastasis | Downregulation of LDLR through MEK/ERK stimulation | [29] |
| Neuronal survival   | ApoE-dependent activation of PKCδ and inactivation of GSK3β | [35] |
| LRP1                | APP trafficking regulation and processing and Aβ clearance | LRP1 antagonist RAP increases cell surface levels of APP and significantly reduce Aβ synthesis. In the absence of LRP1, Aβ production, APP secretion, APP internalization, turnover of full-length APP and stability of APP C-terminal fragments are affected. At the site of the BBB, surface LRP1-mediated extrusion of cerebral Aβ into the luminal side Soluble LRP1 in the periphery sequesters free Aβ in circulation. | [36–39] | Cellular migration and invasion | Expression of MMP-2 and MMP-9 through ERK in human glioblastoma Serpins PN-1-dependent MMP-9 expression through ERK activation in breast cancer | [43,44] |
Table 1. Cont.

| LDLR Family Members | CNS Roles/Neurodegeneration | Molecular Pathway | Refs. | Cancer Related Roles | Molecular Pathway | Refs. |
|---------------------|----------------------------|-------------------|-------|---------------------|-------------------|-------|
| **LRP1**            | Calcium-related cellular processes | ApoE4, but not ApoE3, significantly increased the resting calcium, the calcium response to NMDA-R and the neurotoxicity. | [34] | Cell proliferation, tumor invasion and angiogenesis | LRP1 expression has been linked to neoplastic aggressiveness due to high histological grade and elevated mitotic index. Regeneration of the uPAR receptor system | [45] |
|                     | Neurite outgrowth, synaptic plasticity, learning and memory modulation | Upon TTR binding to LRP2, Src, NMDA-Rs, ERK1/2, CREB and Akt activation and/or a pathway involving RIP and the formation of LRP2-ICD MT-IIA binding to LRP2 stimulates neurite outgrowth via signal transduction pathways activated by the NPxY motifs of LRP2. | [49,52] | Cell survival and proliferation | LRP2 is frequently expressed in lymph node and distant metastasis in gastric and breast cancer patients, promoting cell proliferation and migration. ATRA attenuates proliferation and migration through significant decreases in VLDLR II, while PMA has the opposite effect on VLDLR II, which activates β-catenin/TCF signaling and modulation of MMP-2 and MMP-9. | [7] |
| **VLDLR**           | Regulation of the migration and layering of the neurons in the cortex and the cerebellum | Reelin-induced Dab1 binding to VLDLR activates SFK and Abl families, together with LRP8. Pafah1b complex mediates downstream effects of VLDLR on neuronal migration. | [59,60,119] | Cell proliferation, migration and metastasis | VLDLR II is overexpressed in lymph node and distant metastasis in gastric and breast cancer patients, promoting cell proliferation and migration. ATRA attenuates proliferation and migration through significant decreases in VLDLR II, while PMA has the opposite effect on VLDLR II, which activates β-catenin/TCF signaling and modulation of MMP-2 and MMP-9. | [8,61] |
|                     | Synaptic homeostasis | LRP4 mutant astrocytes suppressed glutamatergic transmission by enhancing the release of ATP. | [63] | | | |
|                     | Synaptic transmission, LTP and cognitive function | LRP4 KO shows deficits in cognitive tasks with aberrant synapse form and function and loss of LTP. | [65] | EMT promotion | LRP4 is overexpressed in papillary thyroid and gastric cancers, where it promotes EMT through PI3K/AKT pathway and modulation of N-cadherin, ZEB1 and EZH2. | [70,71] |
| **LRP4**            | Adult hippocampal neurogenesis | LRP4 mutation blocks NPSC proliferation. Agrin-LRP4-Notch2 signaling is involved in NSPC proliferation. | [66] | Cell proliferation, migration and invasion | LRP5 downregulation affects colony formation and migratory and invasive capacities through PI3K/AKT pathway. miR-140-5p negatively regulates LRP4. | [70,71] |
|                     | Formation and maintenance of the neuromuscular junction | Agrin-LRP4 interaction via MuSK, Dok7 and rapsyn mediates AChR clustering. | [67,68] | | |
Table 1. Cont.

| LDLR Family Members | CNS Roles/Neurodegeneration | Molecular Pathway | Refs. | Cancer Related Roles | Molecular Pathway | Refs. |
|---------------------|-----------------------------|------------------|-------|---------------------|------------------|-------|
| LR11/SorLA          | Regulation of APP processing and Aβ levels | Interaction with APP, enhancement of APP in endosomal compartments and Golgi, modulation of APP processing and reduction of Aβ levels | [72,73] | Cell proliferation | Regulation of endosomal trafficking and oncogenic fitness of HER2, promoting PI3K-dependent HER2 signaling | [78] |
| LRP6                | Synaptic function and integrity | Activation of Wnt signaling | [104] | Cell proliferation, survival and differentiation, tumor growth | Co-receptor for WNT and Wnt activator | [98,103] |
| LRP1B               | Regulation of APP endocytic rate and Aβ levels reduction | Interaction with APP | [118] | Suppression of cell growth, invasion, migration, colony and tumor formation | Reduction of matrix metalloproteinase 2 level and negative regulation of uPAR DNA methylation | [106–108] |

Aβ, amyloid beta; BBB, blood-brain barrier; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; NMDA-R, N-methyl-D-aspartate receptor; uPAR, urokinase-type plasminogen activator receptor; MAP, mitogen-activated protein; CREB, cAMP response element-binding protein; MT, metallothionein; RIP, regulated intramembrane proteolysis; ICD, intracellular domain; SFK, Src kinase family; ATRA, All-trans retinoic acid; PMA, phorbol-12-myristate-13-acetate; LTP, long term potentiation; EMT, epithelial-mesenchymal transition; NPSCs, neural progenitor stem cells; AChR, acetylcholine receptor; PI3K, phosphoinositide 3-kinases; MuSK, muscle-specific Tyr kinase.

3. Apolipoprotein E Receptor 2 (LRP8)

LRP8 (gene name LRP8) is a modular type I transmembrane receptor of the LDLR family whose structure is made of one N-terminal extracellular ligand-binding domain made of seven conserved LA repeats, an EGF domain made of three EGF repeats and one β-propeller and one NPXY motif in the intracellular domain, as described in Figure 1 [120]. LRP8 is involved in many intracellular signaling pathways and cellular responses involving different ligands and co-receptors that will be discussed in detail in Sections 3.1 and 3.2 and in the respective Figures 2 and 3. The intracellular signaling pathways mediated by LRP8 mostly involve the carboxy-terminal NPXY motif [121,122]. This motif adopts in fact a tight hairpin conformation required for binding to phospho-tyrosine binding (PTB) domains or to SH2-SH3 domain-containing proteins. Ligand binding to LRP8, together with different LRP8 spliced variants, also modulates its proteolytic processing that releases C-terminal fragments (CTF) and a transcriptionally active intracellular domain (ICD) [123,124]. A detailed molecular mechanism of LRP8 proteolitic processing is described in Section 3.2.

As mentioned above, LRP8 has several splice variants, expressed in a tissue-specific manner [125–127], whose alteration has also been correlated to sporadic Alzheimer’s disease [128], that modify LRP8 functions such as ligand-binding activity [129], receptor glycosylation and processing [130] and downstream signaling [131]. A well-studied LRP8-spliced variant is the LR7/8B, which harbors high ligand-binding repeats and is known to be a receptor for α-macroglobulin together with LRP1 [132]. Another spliced variant, reported in all placental mammals so far studied and not in marsupials, birds or reptiles, includes exon 19 that encodes for a 59 amino acid proline-rich insert in the cytoplasmic domain of LRP8, which is unique in the LDLR family [133,134]. The human LRP8 unique aminoglycosidic sequence contains two potential SH3 binding motifs, PXXP (two prolines spaced by two other amino acids), suggesting a role in signal transduction pathways involving reelin, PSD-95, NMDA-R and JIPs and the corresponding functional roles in memory and spatial learning [16,18]. Indeed, its deletion in the mouse LR8 gene (exon 19) explains defects in long-term memory storage and spatial learning, most probably due to the interruption of the reelin-mediated activation of NMDA receptors [134].

Additionally, there are variants missing epidermal growth factor repeat B or the O-glycosylation domain [126]. It has been reported that differential LRP8 splicing, together with its glycosylation at the O-linked sugar, regulates the release of the ICD. In this context, Wasser et al., have reported an alternative LRP8 splice variant lacking the O-linked glyco-
lation region that is cleaved more efficiently than the full-length counterparts [130]. More recently, it has been shown that LRP8 isoforms with differing numbers of ligand-binding repeats to generate different amounts of CTFs compared with full-length LRP8 [135].

LRP8 is enriched in the brain, in particular in the neocortex, cerebellum, hippocampus and olfactory bulb [136], and to a minor extent also in the peripheral nervous system such as in the sciatic nerve and Schwann cells [137]. Outside the nervous system, LRP8 can be found in placenta, testis, ovary and platelets and also in immune cells and vascular endothelial and smooth muscle cells [120,138]. Unlike LRP1, LRP8 inactivation has no impact on plasma triglyceride or cholesterol levels. Hence, the association between polymorphisms in the LRP8 gene and CVD risk is likely independent of lipid metabolism but related to LRP8-modulating cellular functions in the vessel wall [139].

3.1. LRP8 and Cancer

Although LRP8 is mainly recognized for its role in CNS-related pathways, scientific evidence also suggests an involvement of the receptor in carcinogenesis. Generally, cancer cells require higher uptake of cholesterol than normal cells in which the receptor-mediated endocytosis of serum LDL enhances the cholesterol content through LDLR. Increases in LDLR and elevated plasma low-density lipoprotein cholesterol (LDL-C) have been reported as features of leukemia, glioblastoma and lung and pancreatic tumors [140]. This is explained by the fact that tumor cells rely on cholesterol for membrane and lipid raft biosynthesis, signaling molecules and other factors in order to meet the fast growth.

In this context, many studies summarized in Table 2 have highlighted the role of LRP8 in the tumorigenesis and progression of several cancers such as osteosarcoma, breast cancer, gastric cancer, hepatocellular carcinoma, lung cancer, prostate cancer and pancreatic cancer [6].

### Table 2. LRP8 in cancer-related molecular pathways. The table summarizes LRP8 main findings in cancer, with the corresponding roles, molecular mechanisms and in vitro and in vivo models used (see references).

| Cancer Types | LRP8 Cancer Roles | Main Findings & Molecular Mechanism | In Vitro E in Vivo Models | Refs. |
|--------------|-------------------|-------------------------------------|--------------------------|-------|
| Osteosarcoma | Cell proliferation and anti-apoptotic effect | LRP8 is overexpressed in osteosarcoma tissues. LRP8 enhances PD-L1 expression via STAT3, evading the host immune system. | Cell lines: MG63 and U2OS | [141] |
| TNBC         | Cell proliferation, anti-apoptotic effect and colony formation | LRP8 is overexpressed in TNBC patients. LRP8 depletion induces arrest of the cell cycle and apoptosis. LRP8 knockdown impairs colony formation. | Cell lines: BT-474, T47D, MCF7, ZR-75-1, SKBR3, HCC1569, HCC1954, BT-20, HCC1143, HCC38, HCC70, MDA-MB-468 and MDA-MB-45 | [142] |
| TNBC         | Tumorigenesis and chemoresistance | LRP8 silencing suppresses BCSCs and tumorigenesis in TNBC via Wnt signaling inhibition. LRP8 KO shifts TNBC cells to a more differentiated phenotype, sensitizing them to chemotherapy. | Cell lines: HCC1937 and SUM149 | [9] |
Table 2. Cont.

| Cancer Types          | LRP8 Cancer Roles | Main Findings & Molecular Mechanism                                                                 | In Vitro E in Vivo Models                  | Refs. |
|-----------------------|-------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------|-------|
| **Gastric cancer**    | Cell migration    | Mycophenolic acid downregulates LRP8, reducing cell migration.                                        | Cell lines: AGS and Hs746T                | [143] |
|                       | Cancer progression| MiR-142 suppresses progression of gastric carcinoma via directly targeting LRP8.                    | Cell lines: AGS, MKN-45, MKN-28, SGC-7901 and BGC-823 | [144] |
| **Hepatocellular carcinoma** | Pharmacoresistance | LRP8-dependent activation of β-catenin pathway suppresses Sorafenib induced apoptosis.              | Cell lines: Huh7 and MHCC-97H            | [145] |
| **Melanoma**          | Suppression of cell invasion and endothelial recruitment | miR-1908, miR-199a-5p, and miR-199a-3p limit ApoE secretion suppressing LRP8 endothelial engagement | Cell lines: TWM-266-4, A375, SK-Mel-28, HT-144, A2058, MeWo, SK-Mel-2, SK-Mel-28, A375, WM-266-4, HT-144, and A2058 In vivo model: xenograft NOD scid mice (MeWo) | [146] |
|                       | Cancer progression and cisplatin resistance | miR-30b-5p inhibits lung cancer cell viability, migration and invasion and enhances cell sensitivity to DDP via targeting LRP8. | Cell lines: A549, A549/DDP, NCI-H1299, NCI-H446 and H1650 In vivo model: xenograft BALB/c nude mice | [147] |
| **Lung cancer**       | Cell proliferation, migration, invasion, EMT, tumor growth (NSCLC) | LRP8 is markedly overexpressed in NSCLC patients with poor clinicopathological characteristics and prognosis. LRP8 KO elicits tumor-suppressive functions by suppressing the Wnt/β-catenin pathway. | Cell lines: 95-D, H1299, H460, HCC-827, A549, PC-9, and H1975 | [148] |
| **Prostate cancer**   | Cancer progression | miR-455-5p inhibits cancer cell migration and invasive abilities through LRP8 downregulation.       | Cell lines: PC3, DU145, and C4-2          | [149] |
| **Pancreatic cancer** | Cell proliferation | ApoE2-LRP8 induces phosphorylation of ERK1/2 to activate c-Myc, promoting cyclin D1, cdc2 and cyclin B1 expression and reducing p21Waf1 activity. | Cell lines: Mia PaCa-2, Capan-2, PANC-1, Bxpc-3 | [150] |

TNBC, Triple-negative breast cancer; BCSCs, Breast cancer stem cells; EMT, Epithelial-to-mesenchymal transition; NSCLC, Non-small cell lung cancer.

In fact, LRP8 is overexpressed in different cancers including osteosarcoma [141] and NSCLC [148], and its overexpression has been significantly correlated with poor clinicopathological features and prognosis. Abnormal LRP8 expression has also been associated with breast cancer progression, where it facilitates cell growth and confers a poor prognosis.
in patients. In particular, Maire et al., demonstrated that LRP8 is more strongly expressed in breast cancer without hormone receptor expression (TNBC and HER2 positive) than in luminal tumors (Luminal A and Luminal B) and that LRP8 depletion promotes apoptosis and impaired cell proliferation and colony formation. These findings have been further confirmed in an in vivo xenograft model where LRP8 depletion slowed tumor growth [142]. Other studies indirectly support the idea of a role of LRP8 in tumorigenesis: Dun et al., have shown that mycophenolic acid severely downregulates the expression of cell surface LRP8, inhibiting cell migration and the invasion of gastric cancer cells [143]; Cai et al., have separately found that LRP8 is responsible for hepatocellular carcinoma cell resistance to sorafenib [145].

In a scenario in which LRP8 seems to have an oncogenic role in many types of cancer, it remains still elusive the biochemical pathways through which LRP8 exerts such activity (Figure 2).

![Figure 2. LRP8 in four main cancer-related molecular pathways.](image)

One hypothetical mechanism is linked to ApoE isoform 2, which is known to have a critical role in cell proliferation and has been identified as a cancer-related molecule. Through its binding to LRP8, ApoE2 induces ERK1/2 phosphorylation and cell cycle activation [150]. (2) LRP8 promotes Wnt-induced β-catenin accumulation, inducing Axin2 transcription [151]. (3) PCSK9 modulates LRP8 endocytosis and signaling by targeting the receptor for lysosomal degradation [152]. (4) LRP8 activates p-STAT3 and its nuclear signaling [141,153].

In osteosarcoma, the overexpression of LRP8 compared with normal tissues, increases phosho-STAT3 (p-STAT3) levels and facilitates its translocation into the nucleus, resulting in an enhancement of mRNA, protein and promoter activity of the programmed death-ligand 1 (PD-L1), which is a marker of metastasis and mortality risk in osteosarcoma [141].

Among the intracellular signaling pathways positively regulated by LRP8, the Wnt/β-catenin is definitely one that links LRP8 to its tumorigenic role [151]. As already reported above, the Wnt/β-catenin pathway is a pleiotropic signal linked to several diseases including cancer. In particular, LRP8 seems to be a positive regulator of the Wnt pathway, increasing Wnt-induced transcriptional responses and promoting Wnt-induced β-catenin accumulation. The LRP8 regulation of the Wnt/β-Catenin pathway has been observed both in triple-negative breast cancer, where LRP8 depletion inhibits breast cancer stem cells, cell proliferation and invasion and epithelial–mesenchymal transition [9], and in NSLC, in which an increase in LRP8 expression facilitates tumor proliferation [148]. Furthermore, in KS483 osteoprogenitor cells, knockdown of LRP8 results in a decrease in the Wnt/β-Catenin pathway, with reduced β-catenin levels and the suppression of Axin2 tran-
scription; as a secondary effect, the depletion of LRP8 decreases osteoblast differentiation and mineralization, whereas LRP8 ectopic expression has the opposite effect [151].

Together with VLDLR and LRPI, LRP8 is also involved in tumor cell growth through its binding to the glycoprotein Proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is known to modulate cholesterol metabolism through its binding to LDLR family members, including LRP8, and promoting their degradation in intracellular acidic compartments. The binding between PCSK9 and the LDLR members occurs between the PCSK9 catalytic subunit and the LDLR EGF-A domain [152]. In this context, in addition to being a key player in the LDL metabolism in the liver and in the brain, PCSK9 is overexpressed in various human cancer cell lines [154].

Komaravolu et al., reported a cell-cycle modulation, not strictly related to cancer, that was mediated by LRP8 through its intracellular interaction with the catalytic subunit of the heterotrimeric enzyme PP2A, a protein complex that is vitally important for the maintenance of normal cell division [155,156]. In this regard, LRP8 participates in mitosis via its interaction with PP2A-C, promoting the formation of active CDC20 to complete cytokinesis. Moreover, since the LRP8-interacting adaptor protein Dab2 is also a substrate for PP2A dephosphorylation, LRP8 may work in concert with Dab2 to modulate cell cycle progression and cytokinesis [156].

LRP8 is also a key mediator in metastatic melanoma, as an ApoE receptor, in parallel with VLDLR and LRPI. According to Pencheva et al., selected miRNAs (miR-1908, miR-199a-5p and miR-199a-3p) limit ApoE secretion, thus suppressing its anti-metastatic action through the engagement of endothelial LRP8 receptor; in this condition, LRP8 no longer suppresses cell invasion and endothelial recruitment, eventually promoting metastasis [146].

Consistent with the above observations, LRP8 was also identified as a target of miR-30b-5p in lung cancer progression and cisplatin resistance. In particular, LRP8 level was markedly increased in lung cancer tissues compared with the control group, apparently acting as an oncogene. In addition, miR-30b-5p inhibits lung cancer cell viability, migration and invasion and enhances cell sensitivity to cisplatin via targeting LRP8, suggesting that miR-30b-5p inhibits lung cancer progression by targeting LRP8 [147]. Lu et al., published a similar work highlighting the role of miR-142 as a gastric cancer suppressor by targeting LRP8 [144]. A similar LRP8 regulation by miR-455-5p has been reported by Arai at al. in prostate cancer [149].

3.2. LRP8 in Neurodegeneration

LRP8 has long been studied for its role in cholesterol transport and metabolism; however, the identification of ApoE4, the major genetic risk factor for developing late-onset Alzheimer’s disease, as one of its ligands has brought attention to its role in CNS-related pathways and neurodegeneration (Figure 3).
LRP8 is mainly known for being a receptor of ApoE, which is produced in various organs, including liver, brain, kidneys, and adrenal glands, and which represents a component of lipoproteins responsible for packaging cholesterol and other fats and carrying them through the bloodstream. LRP8 binds with high affinity only to ApoE-rich β-VLDL, while its affinity for LDL and other VLDL is much lower. In humans, three ApoE isoforms exist that differ at positions 112 and 158 (ApoE2, ApoE3, and ApoE4). ApoE2 has cysteines at positions 112 and 158, ApoE3 has a cysteine at position 112 and an arginine at position 158, and ApoE4 has arginines at positions 112 and 158. The ApoE ε2 allele is associated with the recessive inheritance of hyperlipoproteinemia in patients with type III hyperlipidemia, and the ε4 allele is strongly associated with cardio-cerebrovascular diseases and Alzheimer’s disease. A single copy of the ε4 allele increases AD risk by about 3-fold, with two copies of the ε4 allele increasing disease risk about 12-fold relative to individuals who have 2 copies of the ε3 allele. On the other side, the ε2 allele seems to decrease AD risk by about 0.6. Additional studies have demonstrated that ApoE is closely related to cognitive functions; indeed, ApoE-deficient homozygous mice show impaired working memory accompanied by the age-dependent loss of synaptic proteins. In addition to AD, ApoE has also been reported to have an impact on dementia and synucleinopathy in Parkinson’s disease (PD) dementia and dementia with Lewy bodies as well as in mouse models of synucleinopathy. ApoE is also directly involved...
In the binding and clearance of Aβ, with ApoE ε3 and ApoE ε2 having a higher affinity compared with ApoE ε4 [175,176]. Moreover, these data were also confirmed in in vivo studies showing that knockout ApoE mice crossed with AD mice overexpressing APP exhibit less Aβ deposition compared with those expressing ApoE ε3 or ApoE ε4 [177,178].

In Alzheimer’s disease, Aβ is generated from APP through sequential cleavages, first by β-secretase and then by γ-secretase complex, the latter consisting of at least four components: presenilin (PS, PS1 or PS2), Nicastrin, anterior pharynx-defective-1 (APH-1) and presenilin enhancer-2 (PEN-2) [179,180]. PSs are the crucial catalytic components of γ-secretase, and mutations in PS1 are causative in the majority of familial AD (FAD) cases, likely through a yet-unclear loss of function, while APP overexpression or mutations are causative of FAD, likely favoring amyloidosis and tauopathy [181,182].

Hoe et al., uncovered interactions between LRP8, APP and F-spondin, a component of the extracellular matrix involved in neuronal migration and plasticity in adult and developing brains, suggesting that interaction between extracellular matrix proteins and LRP8 at the cell surface can alter APP processing and decrease Aβ production. LRP8 and APP interaction happens at the extracellular and intracellular levels and increases with the presence of F-spondin, which also mediates increased LRP8 cleavage [158].

The potential clustering of APP and LRP8 modulates their endocytosis, likely altering the cleavage of each receptor, via both extracellular metalloproteinases and intramembranous γ-secretase cleavage. Interestingly, LRP8 expression also correlates with a significant increase in Aβ production and reduced levels of APP-CTFs. The increased Aβ production seems, in turn, to depend on the integrity of the NPYXY endocytosis motif of LRP8; in fact, LRP8 expression increases APP association with lipid rafts and γ-secretase activity, both of which might contribute to increased Aβ production [159]. Moreover, ApoE binding to LRP8 also increases APP endocytosis and Aβ production in an isoform-specific manner [157]. There is therefore a link between ApoE and Aβ that does not depend on their direct interaction but rather on the ability of the different isoforms of ApoE to modify the processing of APP through LRP8, thus representing a bidirectional bridge between cholesterol metabolism and amyloidosis.

In addition to ApoE, another well-known ligand of LRP8 is Reelin: which is ligand as well of the VLDL receptor and that is produced by Cajal–Retzius neurons at the surface of the developing neocortex [183]. Depending on the specific tissue and cell type involved, the binding of Reelin to LRP8 leads to the tyrosine phosphorylation of the adaptor protein Dab1/2 to initiate several signaling cascades such as the activation of PI3K, ERK1/2, Src-family kinases and protein kinase B/Akt. In this context, it is important to highlight that Dab1 is essential for neuronal migration both upon LRP8 or APP activation, suggesting that it is likely through Dab1 that both APP and LRP8 regulate neuronal migration from SVZ toward the cortical plate [59,184]. Furthermore, Stockinger et al., have reported a role of the LRP8–Reelin interaction in the correct positioning of neurons during the embryonic development of the brain.

In the CNS, Reelin is able to regulate APP processing and Aβ production by interacting with APP. Reelin increases cell surface levels of APP and decreased the endocytosis of APP in hippocampal neurons in vitro. In vivo, Reelin levels were increased in the brains of APP knockout mice and decreased in APP-overexpressing mice [185].

Reelin signaling is crucial for many CNS functions such as neuronal migration, dendritic spine development [186], synaptic plasticity [184,187,188] and brain embryonic development [59]. Some of the Reelin functions are played through binding to LRP8; indeed, LRP8 Reelin-regulated neuronal (LRN) enhancer binding modulates learning and memory, which activates synaptic plasticity genes including NMDA receptor NR1, NR2A and NR2B [124]. In addition to its NMDA gene activation, Reelin signaling through LRP8 induces the tyrosine phosphorylation of the receptor NMDA (NR2) subunits, changing their surface distribution and activity and in turn regulating synaptic plasticity, which is further modulated by the differential splicing of the LRP8 cytoplasmic domain [188]. Moreover, LRP8 proline rich 59 amino acid insert is essential for the Reelin-induced en-
hancement of LTP in mice [59]; in this context, interference with Reelin expression or its intracellular signaling pathway has effects on LTP and seizure potential that are partially replicated in LRP8 knockouts. In this context, presenilin mutations have also been linked to Reelin-signaling elements such as phosphatidylinositol 3-kinase and Crk/Dock1/Rac, highlighting a potential correlation of presenilin mutations on synaptic processes with LRP8 [189,190].

Additional studies on LRP8-KO mice have supported a role of LRP8 in neuronal functions, showing in particular a severe impairment in freezing behaviors by performing a classical form of robust associative learning (contextual fear paradigm) reflecting a decline in long-term memory formation [124]. Moreover, LRP8 deficiency in mice has been shown to affect the development of the neocortex, preventing neurons from completing their migration and causing in turn a partial inversion of the neuronal layers in the neocortex [59]. In this context, LRP8 KO/ApoE KO mice have shown cognitive decline greater than that observed in ApoE single-KO mice as indicated by behavioral tests [191].

In addition to the activation of intracellular signaling pathways, the binding of some ligands, especially Reelin, to LRP8 also regulates its proteolytic processing. From the LRP8 full-length mature form (105 kDa), two major proteolytic products have been described so far [88,166–168], the carboxy-terminal fragment generated by extracellular α-secretase (20–25 kDa) and a C-terminal fragment (15–18 kDa) that is produced by γ-secretase cleavage and is similar to AICDs derived by APP processing [166]. In fact, LRP8 is a γ-secretase substrate, like APP and other LDL members such as LRP1 [169], LRP1b [170], LRP2 [171], LRP6 [172], LR11 [173] and VLDLR [174] as well as many other substrates including Notch [175–178]. The LRP8 C-terminal fragment produced by γ-secretase cleavage appears to translocate into the nucleus where it inhibits Reelin transcription, creating a negative feedback loop for Reelin levels; indeed, depletion of Presenilin1, the catalytic component of γ-secretase, elevates the levels of both Reelin and LRP8 in mouse brain [123]. Telese et al., showed that the nuclear translocation of the LRP8 CTF, derived from γ-secretase cut, stimulates specific enhancers critically involved in hippocampus-dependent learning and memory, implying that Reelin can impact genes related to learning and memory via the LRP8 γ-CTF and that this process might be attenuated by PS1 mutations [124]. In this scenario, in which the processing of LRP8 modulates its functions, Reelin causes a reduction of the full-length receptor, probably enhancing its proteolysis by a sheddase after ligand-stimulated internalization. PS1 mutations show impaired γ-secretase activity relatively to LRP8 and an accumulation of its C-terminal fragments after Reelin exposure; this last effect is potentiated by co-exposure to DAPT, a γ-secretase inhibitor [192].

In addition to the ligands already mentioned, ApoE, F-Spondin and Reelin, other proposed LRP8 ligands are: (1) trombospondin-1, expressed in the subventricular zone and throughout the rostral migratory stream, where it acts on LRP8 by promoting neuroblast chain migration [193]; (2) clusterin (apolipoprotein J), which modulates a cell proliferative signal in migrating neuronal precursors of SVZ explants, in vitro, via Dab1 activation [194]; (3) selenoprotein P, a mediator of selenium transport whose binding with LRP8 has been observed in the brain, testis and bone. Selenium and its carrier protein, selenoprotein P, have been reported to have important roles in maintaining optimal brain function as well as in relevant AD-related pathways in addition to regulating the development and the immune system and having antitumor properties due to their strong antioxidant activities [195]. Epidemiological studies have shown a significant positive correlation between selenium level and cognitive ability [196] and that blood selenium level gradually decreases with age [197]. Furthermore, selenium levels change significantly in the brain and blood of patients with various neurodegenerative diseases such as AD, PD, multiple sclerosis and Batten’s disease [198]. In this context, LRP8 KO mice have shown similar phenotypes of selenoprotein P KO mice in the brain and in the testis, highlighting the biological significance of the receptor-mediated uptake of selenium. Indeed, lowering brain Se levels by the genetic inactivation of selenoprotein P, or its neuronal receptor LRP8 [199,200], has been shown to lead to spontaneous neurological deficits and neurodegeneration.
An overview of the LRP8 roles and molecular mechanisms in CNS and neurodegeneration is reported in Table 3.

Table 3. LRP8 in CNS- and neurodegeneration-related molecular pathways. The table summarizes main findings in CNS and neurodegeneration correlating LRP8 and its ligand binding to corresponding roles, molecular mechanisms and in vitro and in vivo models used in the experimental studies taken into consideration (see references).

| LRP8 Interactors | Roles in CNS and Neurodegeneration | LRP8 Main Findings & Molecular Mechanism Related to CNS | In Vitro E in Vivo Models | Refs. |
|------------------|-----------------------------------|-------------------------------------------------------|--------------------------|-------|
| ApoE             | Neurodegeneration                  | Increase in APP endocytosis and Aβ production via X11α or X11β (X11α/β) | Neuroblastoma N2a cells  | [157] |
| Synaptic plasticity |                                   | Activation of synaptic plasticity genes mediated by the activation of neuronal enhancers | Primary cortical neurons/heterozygous Reeler and LRP8-KO mice | [124] |
| Reelin           |                                   | Enhancement of LRP8 proteolytic processing, followed by LRP8-ICD induced transcription | | |
|                  |                                   | Modulation of NMDA-R phosphorylation via SFKs and Dab1 followed by increased Calcium influx | Primary wild-type cortical neurons/Dab1 knock-out neurons | [163] |
|                  | Control of neuronal migration and cellular layer formation in the developing brain | Partial inversion of the neuronal layers in the neocortex | VLDL and LRP8 KO mice | [59] |
| Neurodegeneration |                                   | Activation of the signaling pathway involving Dab1-P13K-AKT leading to the inhibition of GSK3β and in turn phosphorylation of tau | Primary neurons | [161] |
| Trombospondin-1 (THBS-1) | Postnatal neuronal migration | Promotion of neuroblast chain migration | SVZ explants from wild-type mice, ApoER2−/− VLDLR−/− mice and THBS-1−/− mice on a C57BL6/J background | [193] |
| Clusterin        | Postnatal neuronal migration       | Modulation of a cell proliferative signal in migrating neuronal precursors via Dab1-P13K/Akt signal | SVZ explants from wild-type mice | [194] |
| Selenoprotein P (Sepp1) | Preservation of neurological function and survival | Selenium transport | Sepp1−/− and Sepp1+/+ male mice ApoER2−/− mice (strain name, B6;129S6-Lrp8tm1Her/J) | [199] |
| F-Spondin        | Neurodegeneration                  | LRP8 cleavage increase and Aβ production decrease | COS7 and HEK293 cells transfected with reelin, spondin, thrombospondin or F-spondin | [158] |

SVZ, Subventricular zone.

4. Final Remarks

LDLR, and LRP8 in particular, are receptors that through multiple pathways and mechanisms seems to play a role both in the modulation of neuronal activity and in the regulation of cell proliferation. In this context, several studies have proposed a potential link between oncological and neurodegenerative pathways but have rarely found a common denominator. Using an obvious oversimplification, we could say that high levels of LRP8 manifest a correlation with proliferation and metastasis in cancer cells and tissues, while functions related to neuronal migration, amyloidosis and neurodegeneration, in a broad
sense, are likely modulated by the proteolytic processing of LRP8, which however has
never been fully defined in its complexity.

Some features of LRP8 are, from this point of view, relevant: from one side, the same
pathways (for example Wnt) foresee LRP8 as pivotal regulator both in degeneration like
Alzheimer’s and in tumor genesis such as in breast cancer; from the other side, ApoE, the
most famous ligand of LRP8, is at the crossroads between metastatic proliferation and
Alzheimer’s-type neurodegeneration. At present, it is not clear what is the main pathway
through which LRP8 can influence tumor proliferation or whether there is a prevalent
mechanism in which it is involved. Specific studies on cancer stem cells and using in vivo
xenograft animal models will need to clarify these aspects before LRP8 can be defined as a
potential therapeutic marker.

In addition, it is well-known that the processing of many receptors involved in onco-
logical and/or neurodegenerative pathways depends on the action of the intramembrane
protease γ-secretase. In fact, γ-secretase inhibitors are still used in oncological trials and
in the recent past have been used, with unfortunately negative results, to treat patients
suffering from Alzheimer’s disease. Regarding LRP8, it is not known if its processing by
γ-secretase is altered in patients with Alzheimer’s disease, and the consequences of this
processing on amyloid formation are still underexplored.

After putting together the pieces of the puzzle, there are still obvious questions
that remain open and whose answers could lead not only to decipher key points in the
intersection between oncological and neurodegenerative pathways but also to define
new therapeutic targets in both fields: One, what is the exact role of ApoE/LRP8 in
tumorigenesis and Alzheimer’s? Two, how important are the different isoforms of splicing
and the complex processing of LRP8 to defining its functions in AD and cancer? Three,
can amyloidosis and cell proliferation in cancer be reversed targeting ApoE/LRP8? In
this context, it is sadly remarkable that the hypothesis of a loss of function of γ-secretase
in familial AD mutants, relative to other substrates than APP, has never been studied in
depth [201,202]. The answers to these questions will hopefully lead to a greater knowledge
of the molecular mechanisms in which LDLR receptors are involved, and LRP8 in particular,
to develop new diagnostic and therapeutic tools that can be used both in oncology and
in some neurodegenerative conditions such as the Alzheimer’s dementia and pathologies
related to aberrant neuronal migration.

Author Contributions: Conceptualization, C.P., D.P. and C.R.; Bibliographic investigation, V.D.L.,
A.M., E.F. and M.F.; data curation, A.M., D.M., M.R. and M.F.; writing—original draft preparation, D.P.
and C.P.; writing—review and editing, D.P., S.C., V.D.L. and M.Z.; supervision, S.C. and C.P.; funding
acquisition, C.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by “Scientific projects referred to in art. 1 paragraph 34 and 34 bis,
L. 12.23.1996, n. 662 for the implementation of the objectives of a priority nature and of national
importance (D1513000430001)” to C.R.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors wish to thank Francesco Caciagli and Patrizia di Iorio for their
tireless scientific and knowledge support.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Karanth, S.D.; Katsumata, Y.; Nelson, P.T.; Fardo, D.W.; McDowell, J.K.; Schmitt, F.A.; Kryscio, R.J.; Browning, S.R.; Braithwaite, D.; Arnold, S.M.; et al. Cancer Diagnosis Is Associated with a Lower Burden of Dementia and Less Alzheimer’s-Type Neuropathology. *Brain* 2022, 145, 2518–2527. [CrossRef] [PubMed]

2. Ospina-Romero, M.; Glymour, M.M.; Hayes-Larson, E.; Mayeda, E.R.; Graff, R.E.; Brenowitz, W.D.; Ackley, S.F.; Witte, J.S.; Kobayashi, L.C. Association Between Alzheimer Disease and Cancer with Evaluation of Study Biases. *JAMA Netw. Open* 2020, 3, e202515. [CrossRef]

3. Driver, J.A. Understanding the Link between Cancer and Neurodegeneration. *J. Geriatr. Oncol.* 2012, 3, 58–67. [CrossRef]

4. Li, Y.; Cam, J.; Bu, G. Low-Density Lipoprotein Receptor Family. *Mol. Neurobiol.* 2001, 23, 53–67. [CrossRef]

5. Lane-Donovan, C.E.; Phillips, G.T.; Herz, J. More Than Cholesterol Transporters: Lipoprotein Receptors in CNS Function and Neurodegeneration. *Neuron* 2014, 83, 771–787. [CrossRef] [PubMed]

6. Roslan, Z.; Muhamad, M.; Selvaratnam, L.; Ab-Rahim, S. The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review. *J. Oncol.* 2019, 2019, e4536302. [CrossRef] [PubMed]

7. Andersen, R.K.; Hammer, K.; Hager, H.; Christensen, J.N.; Ludvigsen, M.; Honoré, B.; Thomsen, M.-B.H.; Madsen, M. Melanoma Tumors Frequently Acquire LRP2/Megalin Expression, Which Modulates Melanoma Cell Proliferation and Survival Rates. *Pigment. Cell Melanoma Res.* 2015, 28, 267–280. [CrossRef]

8. Yang, P.; Liu, Z.; Wang, H.; Tian, J.; Li, Y.; Zong, Y.; Qu, S. Enhanced Activity of Very Low Density Lipoprotein Receptor II Promotes SGC7901 Cell Proliferation and Migration. *Life Sci.* 2009, 84, 402–408. [CrossRef]

9. Lin, C.-C.; Lo, M.-C.; Moody, R.; Jiang, H.; Harouaka, R.; Stevers, N.; Tinsley, S.; Gasparyan, M.; Wicha, M.; Sun, D. Targeting LRP8 Inhibits Breast Cancer Stem Cells in Triple-Negative Breast Cancer. *Cancer Lett.* 2018, 438, 165–173. [CrossRef]

10. Gent, J.; Braakman, I. Low-Density Lipoprotein Receptor Structure and Folding. *CMLS Cell. Mol. Life Sci.* 2004, 61, 2461–2470. [CrossRef]

11. Andersen, O.M.; Dagil, R.; Kragelund, B.B. New Horizons for Lipoprotein Receptors: Communication by β-Propellers. *J. Lipid. Res.* 2013, 54, 2763–2774. [CrossRef] [PubMed]

12. Długosz, P.; Nimpf, J. The Reelin Receptors Apolipoprotein E Receptor 2 (ApoER2) and VLDL Receptor. *Int. J. Mol. Sci.* 2018, 19, 3090. [CrossRef] [PubMed]

13. Borg, J.P.; Ooi, J.; Levy, E.; Margolis, B. The Phosphotyrosine Interaction Domains of X11 and FE65 Bind to Distinct Sites on the YENPTY Motif of Amyloid Precursor Protein. *Mol. Cell Biol.* 1996, 16, 6229–6241. [CrossRef] [PubMed]

14. Batzer, A.G.; Blaikie, P.; Nelson, K.; Schlessinger, J.; Margolis, B. The Phosphotyrosine Interaction Domain of Shc Binds an LNXNPY Motif on the Epidermal Growth Factor Receptor. *Mol. Cell Biol.* 1995, 15, 4403–4409. [CrossRef]

15. Calderwood, D.A.; Yan, B.; de Pereda, J.M.; Alvarez, B.G.; Fujioka, Y.; Liddington, R.C.; Ginsberg, M.H. The Phosphotyrosine Binding-like Domain of Talin Activates Integrins. *J. Biol. Chem.* 2002, 277, 21749–21758. [CrossRef] [PubMed]

16. Gotthardt, M.; Trommsdorff, M.; Nevitt, M.F.; Shelton, J.; Richardson, J.A.; Stockinger, W.; Nimpf, J.; Herz, J. Interactions of the Low Density Lipoprotein Receptor Gene Family with Cytosolic Adaptor and Scaffold Proteins Suggest Diverse Biological Functions in Cellular Communication and Signal Transduction. *J. Biol. Chem.* 2000, 275, 25616–25624. [CrossRef]

17. Trommsdorff, M.; Borg, J.-P.; Margolis, B.; Herz, J. Interaction of Cytosolic Adaptor Proteins with Neuronal Apolipoprotein E Receptors and the Amyloid Precursor Protein. *J. Biol. Chem.* 1998, 273, 33556–33560. [CrossRef]

18. Stockinger, W.; Brandes, C.; Fasching, D.; Hermann, M.; Gotthardt, M.; Herz, J.; Schneider, W.J.; Nimpf, J.; The Reelin Receptor ApoER2 Recruits JNK-Interacting Proteins-1 and -2. *J. Biol. Chem.* 2000, 275, 25625–25632. [CrossRef]

19. Go, G.; Mani, A. Low-Density Lipoprotein Receptor (LDLR) Family Orchestrates Cholesterol Homeostasis. *Yale J. Biol. Med.* 2012, 85, 19–28.

20. Weisgraber, K.H. Apolipoprotein E: Structure-Function Relationships. *Adv. Protein. Chem.* 1994, 45, 249–302. [CrossRef]

21. Boyles, J.K.; Pitas, R.E.; Wilson, E.; Mahley, R.W.; Taylor, J.M. Apolipoprotein E Associated with Astrocytic Glia of the Central Nervous System and with Nonmyelinating Glia of the Peripheral Nervous System. *J. Clin. Investig.* 1985, 76, 1501–1513. [CrossRef] [PubMed]

22. Mahley, R.W. Apolipoprotein E: Cholesterol Transporter Protein with Expanding Role in Cell Biology. *Science* 1988, 240, 622–630. [CrossRef] [PubMed]

23. Johnson, L.A.; Olsen, R.H.J.; Merkens, L.S.; DeBarber, A.; Steiner, R.D.; Sullivan, P.M.; Maeda, N.; Raber, J. Apolipoprotein E–Low Density Lipoprotein Receptor Interaction Affects Spatial Memory Retention and Brain ApoE Levels in an Isoform-Dependent Manner. *Neurobiol. Dis.* 2014, 64, 150–162. [CrossRef] [PubMed]

24. Abisambra, J.F.; Fiorelli, T.; Padmanabhan, J.; Neame, P.; Wefes, I.; Potter, H. LDLR Expression and Localization Are Altered in Mouse and Human Cell Culture Models of Alzheimer’s Disease. *PLoS ONE* 2010, 5, e8556. [CrossRef] [PubMed]

25. Katsouri, L.; Georgopoulos, S. Lack of LDL Receptor Enhances Amyloid Deposition and Decreases Glial Response in an Alzheimer’s Disease Mouse Model. *PLoS ONE* 2011, 6, e21880. [CrossRef] [PubMed]

26. Fryer, J.D.; Demattos, R.B.; McCormick, L.M.; O’Dell, M.A.; Spinner, M.L.; Bales, K.R.; Paul, S.M.; Sullivan, P.M.; Parsadanian, M.; Bu, G.; et al. The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plate Pathology in PDAPP Mice. *J. Biol. Chem.* 2005, 280, 25754–25759. [CrossRef]
27. Kim, J.; Castellano, J.M.; Jiang, H.; Basak, J.M.; Parsadanian, M.; Pham, V.; Mason, S.M.; Paul, S.M.; Holtzman, D.M. Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance. *Neuron* 2009, 64, 632–644. [CrossRef] [PubMed]

28. Castellano, J.M.; Deane, R.; Gottesdiener, A.J.; Vergheze, P.B.; Stewart, F.R.; West, T.; Paoletti, A.C.; Kasper, T.R.; DeMattos, R.B.; Zlokovic, B.V.; et al. Low-Density Lipoprotein Receptor Overexpression Enhances the Rate of Brain-to-Blood Aβ Clearance in a Mouse Model of β-Amyloidosis. *Proc. Natl. Acad. Sci. USA* 2012, 109, 15502–15507. [CrossRef] [PubMed]

29. Chen, Z.; Chen, L.; Sun, B.; Liu, D.; He, Y.; Qi, L.; Li, G.; Han, Z.; Zhan, L.; Zhang, S.; et al. LDLR Inhibition Promotes Hepatocellular Carcinoma Proliferation and Metastasis by Elevating Intracellular Cholesterol Synthesis through the MEK/ERK Signaling Pathway. *Mol. Metab.* 2021, 51, 101230. [CrossRef]

30. Lin, L.; Hu, K. LRP-1: Functions, Signaling and Implications in Kidney and Other Diseases. *Int. J. Mol. Sci.* 2014, 15, 22887–22901. [CrossRef]

31. Zlokovic, B.V.; Deane, R.; Sagare, A.P.; Bell, R.D.; Winkler, E.A. Low-Density Lipoprotein Receptor-Related Protein-1: A Serial Clearance Homeostatic Mechanism Controlling Alzheimer’s Amyloid β-Peptide Elimination from the Brain. *J. Neurochem.* 2010, 115, 1077–1089. [CrossRef]

32. Sagare, A.P.; Deane, R.; Zlokovic, B.V. Low-Density Lipoprotein Receptor-Related Protein 1: A Physiological Aβ Homeostatic Mechanism with Multiple Therapeutic Opportunities. *Pharmacol. Ther.* 2012, 136, 94–105. [CrossRef] [PubMed]

33. Kaneyoshi, T.; Bu, G. The Low-Density Lipoprotein Receptor-Related Protein 1 and Amyloid-β Clearance in Alzheimer’s Disease. *Front. Aging Neurosci.* 2014, 6, 93. [CrossRef] [PubMed]

34. Qiu, Z.; Crutcher, K.A.; Hymen, B.T.; Rebeck, G.W. ApoE Isoforms Affect Neuronal N-Methyl-D-Aspartate Calcium Responses and Toxicity via Receptor-Mediated Processes. *Neuroscience* 2003, 122, 291–303. [CrossRef] [PubMed]

35. Hayashi, H.; Campenot, R.B.; Vance, D.E.; Vance, J.E. Apolipoprotein E-Containing Lipoproteins Protect Neurons from Apoptosis via a Signaling Pathway Involving Low-Density Lipoprotein Receptor-Related Protein-1. *J. Neurosci.* 2007, 27, 1933–1941. [CrossRef]

36. Ulery, P.G.; Beers, J.; Mikhailenko, I.; Tanzi, R.E.; Rebeck, G.W.; Hyman, B.T.; Strickland, D.K. Modulation of Beta-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-Related Protein (LRP). Evidence That LRP Contributes to the Pathogenesis of Alzheimer’s Disease. *J. Biol. Chem.* 2000, 275, 7410–7415. [CrossRef]

37. Pietrzik, C.U. The Cytoplasmic Domain of the LDL Receptor-Related Protein Regulates Multiple Steps in APP Processing. *EMBO J.* 2002, 21, 5691–5700. [CrossRef] [PubMed]

38. Ramanathan, A.; Nelson, A.R.; Sagare, A.P.; Zlokovic, B.V. Impaired Vascular-Mediated Clearance of Brain Amyloid Beta in Alzheimer’s Disease: The Role, Regulation and Restoration of LRP1. *Front. Aging Neurosci.* 2015, 7, 136. [CrossRef] [PubMed]

39. Yepes, M.; Sandkvist, M.; Moore, E.G.; Bugge, T.H.; Strickland, D.K.; Lawrence, D.A. Tissue-Type Plasminogen Activator Induces Opening of the Blood-Brain Barrier via the LDL Receptor–Related Protein. *J. Clin. Investig.* 2003, 112, 1533–1540. [CrossRef] [PubMed]

40. Herz, J.; Clouthier, D.E.; Hammer, R.E. LDL Receptor-Related Protein Internalizes and Destroys UPA-PAI-1 Complexes and Is Essential for Embryo Implantation. *Cell* 1992, 71, 411–421. [CrossRef]

41. May, P.; Rohlmann, A.; Bock, H.H.; Zurhove, K.; Marth, J.D.; Schomburg, E.D.; Noebels, J.L.; Beffert, U.; Sweatt, J.D.; Weeber, E.J.; et al. Neuronal LRPI Functionally Associates with Postsynaptic Proteins and Is Required for Normal Motor Function in Mice. *Mol. Cell Biol.* 2004, 24, 8872–8883. [CrossRef] [PubMed]

42. Liu, Q.; Trotter, J.; Zhang, J.; Peters, M.M.; Cheng, H.; Bao, J.; Han, X.; Weeber, E.J.; Bu, G. Neuronal LRPI Knockout in Adult Mice Leads to Impaired Brain Lipid Metabolism and Progressive, Age-Dependent Synapse Loss and Neurodegeneration. *J. Neurosci.* 2010, 30, 17068–17078. [CrossRef] [PubMed]

43. Song, H.; Li, Y.; Lee, J.; Schwartz, A.L.; Bu, G. Low-Density Lipoprotein Receptor-Related Protein 1 Promotes Cancer Cell Migration and Invasion by Inducing the Expression of Matrix Metalloproteinases 2 and 9. *Cancer Res.* 2009, 69, 879–886. [CrossRef]

44. Fayard, B.; Bianchi, F.; Dey, J.; Moreno, E.; Djaffer, S.; Hynes, N.E.; Monard, D. The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRPI–Mediated MMP-9 Expression. *Cancer Res.* 2009, 69, 5690–5698. [CrossRef] [PubMed]

45. Catasus, L.; Gallardo, A.; Llorente-Cortes, V.; Escuin, D.; Muñoz, J.; Tibau, A.; Peiro, G.; Barnadas, A.; Lerma, E. Low-Density Lipoprotein Receptor–Related Protein 1 Is Associated with Proliferation and Invasiveness in Her-2/Neu and Triple-Negative Breast Carcinomas. *Hum. Pathol.* 2011, 42, 1581–1588. [CrossRef] [PubMed]

46. Christensen, E.I.; Birm, H.; Storm, T.; Weyer, K.; Nielsen, R. Endocytic Receptors in the Renal Proximal Tubule. *Physiology* 2012, 27, 223–236. [CrossRef] [PubMed]

47. Carro, E.; Spuch, C.; Trejo, J.L.; Antequera, D.; Torres-Aleman, I. Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I. *J. Neurosci.* 2005, 25, 10884–10893. [CrossRef]

48. Gajera, C.R.; Emich, H.; Lioubinski, O.; Christ, A.; Beckervordersandforth-Bonk, R.; Yoshikawa, K.; Bachmann, S.; Christensen, E.I.; Götz, M.; Kempermann, G.; et al. LR2P in Ependymal Cells Regulates BMP Signaling in the Adult Neurogenic Niche. *J. Cell Sci.* 2010, 123, 1922–1930. [CrossRef]
Gomes, J.R.; Lobo, A.; Nogueira, R.; Terceiro, A.F.; Costelha, S.; Lopes, I.M.; Magalhães, A.; Summaville, T.; Saraiva, M.J. Neuronal Megalin Mediates Synaptic Plasticity-a Novel Mechanism Underlying Intellectual Disabilities in Megalin Gene Pathologies. *Brain Commun.* 2020, 2, fcca135. [CrossRef] [PubMed]

Marzolo, M.-P.; Farfán, P. New Insights into the Roles of Megalin/LRP2 and the Regulation of Its Functional Expression. *Biol. Res.* 2011, 44, 89–105. [CrossRef] [PubMed]

Gomes, J.R.; Sárkány, Z.; Teixeira, A.; Nogueira, R.; Cabrito, I.; Soares, H.; Wittelsberger, A.; Stortelers, C.; Macedo-Ribeiro, S.; Vanlandschoot, P.; et al. Anti-TTR Nanobodies Allow the Identification of TTR Neurotogenic Epitope Associated with TTR-Megalin Neurotrophic Activities. *ACS Chem. Neurosci.* 2019, 10, 704–715. [CrossRef]

Fitzgerald, M.; Naim, P.; Bartlett, C.A.; Chung, R.S.; West, A.K.; Beazley, L.D. Metallothionein-IIA Promotes Neurite Growth via the Megalin Receptor. *Exp. Brain Res.* 2007, 183, 171–180. [CrossRef] [PubMed]

Alvira-Botero, X.; Pérez-González, R.; Spuch, C.; Vargas, T.; Antequera, D.; Garzón, M.; Bermejo-Pareja, F.; Carro, E. Megalin Interacts with APP and the Intracellular Adapter Protein F65 in Neurons. *Mol. Cell. Neurosci.* 2010, 45, 306–315. [CrossRef] [PubMed]

Pober, B.R.; Longoni, M.; Noonan, K.M. A Review of Donnai-Barrow and Facio-Oculo-Acoustico-Renal (DB/FOAR) Syndrome: Clinical Features and Differential Diagnosis. *Birth Defects Res. Part. A. Clin. Mol. Teratol.* 2009, 85, 76–81. [CrossRef] [PubMed]

Vargas, T.; Bulildo, M.J.; Martinez-García, A.; Antequera, D.; Clarimon, J.; Rosich-Estrago, M.; Martín-Requero, A.; Mateo, I.; Rodríguez-Rodríguez, E.; Villa-Cuadra, E.; et al. A Megalin Polymorphism Associated with Promoter Activity and Alzheimer’s Disease Risk. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* 2010, 153B, 895–902. [CrossRef]

Holt, S.K.; Karyadi, D.M.; Kwon, E.M.; Stanford, J.L.; Nelson, P.S.; Ostrander, E.A. Association of Megalin Genetic Polymorphisms with Prostate Cancer Risk and Prognosis. *Clin. Cancer Res.* 2008, 14, 3823–3831. [CrossRef] [PubMed]

Ge, S.; Li, B.; Li, Y.; Li, Z.; Liu, Z.; Chen, Z.; Wu, J.; Gao, J.; Shen, L. Genomic Alterations in Advanced Gastric Cancer Endoscopic Biopsy Samples Using Targeted Next-Generation Sequencing. *Am. J. Cancer Res.* 2017, 7, 1540–1553.

Trommsdorff, M.; Gotthardt, M.; Hiesberger, T.; Shelton, J.; Stockinger, W.; Nimpf, J.; Hammer, R.E.; Richardson, J.A.; Herz, J.; Reeler/Disabled-like Disruption of Neuronal Migration in Knockout Mice Lacking the VLDL Receptor and ApoE Receptor 2. *Cell* 1999, 97, 689–701. [CrossRef]

Zhang, G.; Assadi, A.H.; McNeill, R.S.; Beffert, U.; Wynshaw-Boris, A.; Herz, J.; Clark, G.D.; D’Arcangelo, G. The Pafah1b Complex Interacts with the Reelin Receptor VLDLR. *PLoS ONE* 2007, 2, e252. [CrossRef] [PubMed]

He, L.; Lu, Y.; Wang, P.; Zhang, J.; Yin, C.; Su, Q. Up-Regulated Expression of Type II Very Low Density Lipoprotein Receptor Correlates with Cancer Metastasis and Has a Potential Link to β-Catenin in Different Cancers. *BMC Cancer* 2010, 10, 601. [CrossRef] [PubMed]

Leupin, O.; Piters, E.; Halleux, C.; Hu, S.; Kramer, I.; Morvan, F.; Bouwmeester, T.; Schirle, M.; Bueno-Lozano, M.; Fuentes, F.J.R.; et al. Bone Overgrowth-Associated Mutations in the LR4P Gene Impair Sclerostin Facilitator Function. *J. Biol. Chem.* 2011, 286, 19489–19500. [CrossRef] [PubMed]

Sun, X.-D.; Li, L.; Liu, F.; Huang, Z.-H.; Bean, J.C.; Jiao, H.-F.; Barik, A.; Kim, S.-M.; Wu, H.; Shen, C.; et al. Lrp4 in Astrocytes Modulates Glutamatergic Transmission. *Nat. Neurosci.* 2016, 19, 1010–1018. [CrossRef] [PubMed]

Zhang, H.; Chen, W.; Tan, Z.; Zhang, L.; Dong, Z.; Cui, W.; Zhao, K.; Wang, H.; Jing, H.; Cao, R.; et al. A Role of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytic Aβ Clearance. *J. Neurosci.* 2020, 40, 5347–5361. [CrossRef]

Gomez, A.M.; Froemke, R.C.; Burden, S.J. Synaptic Plasticity and Cognitive Function Are Disrupted in the Absence of Lrp4. *Neuron* 2018, 10, 601. [CrossRef] [PubMed]

Zhang, B.; Luo, S.; Wang, Q.; Suzuki, T.; Xiong, W.C.; Mei, L. LRP4 Serves as a Coreceptor of Agrin. *Biochem. Biophys. Res. Commun.* 2012, 409, 5347–5361. [CrossRef] [PubMed]

Kim, N.; Stiegler, A.L.; Cameron, T.O.; Hallock, P.T.; Gomez, A.M.; Huang, J.H.; Hubbard, S.R.; Dustin, M.L.; Burden, S.J. LRP4 Is a Receptor for Agrin and Forms a Complex with MuSK. *Cell* 2008, 135, 334–342. [CrossRef] [PubMed]

Zhang, B.; Luo, S.; Wang, Q.; Suzuki, T.; Xiong, W.C.; Mei, L. LRP4 Serves as a Coreceptor of Agrin. *Neuron* 2008, 60, 285–297. [CrossRef] [PubMed]

Zong, Y.; Zhang, B.; Gu, S.; Lee, K.; Zhou, J.; Yao, G.; Figueiredo, D.; Perry, K.; Mei, L.; Jin, R. Structural Basis of Agrin–LRP4–MuSK Signaling. *Genes Dev.* 2012, 26, 247–258. [CrossRef] [PubMed]

Zhou, X.; Xia, E.; Bhandari, A.; Zheng, C.; Xiang, J.; Guan, Y.; Zhang, X. LRP4 Promotes Proliferation, Migration, and Invasion in Papillary Thyroid Cancer. *Biochem. Biophys. Res. Commun.* 2018, 503, 257–263. [CrossRef] [PubMed]

Mao, Z.; Wang, Z.; Zhang, S.; Pu, Y.; Wang, J.; Zhang, T.; Long, Y.; Liu, Y.; Ma, Y.; Zhu, J. LRP4 Promotes Migration and Invasion of Gastric Cancer under the Regulation of MicroRNA-140-5p. *CMB* 2020, 29, 245–253. [CrossRef] [PubMed]

Offe, K.; Dodson, S.E.; Shoemaker, J.T.; Fritz, J.J.; Gearing, M.; Levey, A.I.; Lah, J.J. The Lipoprotein Receptor LR11 Regulates Amyloid Beta Production and Amyloid Precursor Protein Traffic in Endosomal Compartments. *J. Neurosci.* 2006, 26, 1596–1603. [CrossRef] [PubMed]
98. Raisch, J.; Côté-Biron, A.; Rivard, N. A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers. *Cancers* **2019**, *11*, 1162. [CrossRef]

99. Deng, D.; Zhang, Y.; Bao, W.; Kong, X. Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Rs10845498 Polymorphism Is Associated with a Decreased Risk of Non-Small Cell Lung Cancer. *Int. J. Med. Sci.* **2014**, *11*, 685–690. [CrossRef]

100. Tung, E.K.-K.; Wong, B.Y.-C.; Yau, T.-O.; Ng, I.O.-L. Uptregulation of the Wnt Co-Receptor LRP6 Promotes Hepatocarcinogenesis and Enhances Cell Invasion. *PLoS ONE* **2012**, *7*, e36565. [CrossRef]

101. Rismani, E.; Fazeli, M.S.; Mahmooodzadeh, H.; Movassagh, A.; Azami, S.; Karimipoor, M.; Teimoori-Toolabi, L. Pattern of LRP6 Gene Expression in Tumoral Tissues of Colorectal Cancer. *Cancer Biomark.* **2017**, *13*, 151–159. [CrossRef] [PubMed]

102. Garg, B.; Giri, B.; Majumder, K.; Dudeja, V.; Banerjee, S.; Saluja, A. Modulation of Post-Translational Modifications in β-Catenin and LRP6 Inhibits Wnt Signaling Pathway in Pancreatic Cancer. *Cancer Lett.* **2017**, *386*, 64–72. [CrossRef] [PubMed]

103. Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G. Wnt Signaling Activation and Mammary Gland Hyperplasia in MMTV–LRP6 Transgenic Mice: Implication for Breast Cancer Tumorigenesis. *Oncogene* **2010**, *29*, 539–549. [CrossRef] [PubMed]

104. Liu, C.-C.; Tsai, C.-W.; Deak, F.; Rogers, J.; Penuliar, M.; Sung, Y.M.; Maher, J.N.; Fu, Y.; Li, X.; Xu, H.; et al. Deficiency in LRP6-Mediated Wnt Signaling Contributes to Syndactylic Abnormalities and Amyloid Pathology in Alzheimer’s Disease. *Neuron* **2014**, *84*, 63–77. [CrossRef]

105. Liu, C.X.; Li, Y.; Obermoeller-McCormick, L.M.; Schwartz, A.L.; Bu, G. The Putative Tumor Suppressor LRP1B, a Novel Member of the Low Density Lipoprotein (LDL) Receptor Family, Exhibits Both Overlapping and Distinct Properties with the LDL Receptor-Related Protein. *J. Biol. Chem.* **2001**, *276*, 28889–28896. [CrossRef]

106. Li, Y.; Knisely, J.M.; Li, Y.; McCormick, L.M.; Wang, J.; Henkin, J.; Schwartz, A.L.; Bu, G. Low Density Lipoprotein (LDL) Receptor-Related Protein 1B Impairs Urokinase Receptor Regeneration on the Cell Surface and Inhibits Cell Migration. *J. Biol. Chem.* **2002**, *277*, 42366–42371. [CrossRef]

107. Lu, Y.-J.; Wu, C.-S.; Li, H.-P.; Liu, H.-P.; Lu, C.-Y.; Leu, Y.-W.; Wang, C.-S.; Chen, L.-C.; Lin, K.-H.; Chang, Y.-S. Abrerrant Methylation Impairs Low Density Lipoprotein Receptor-Related Protein 1B Tumor Suppressor Function in Gastric Cancer. *Genes Chromosomes Cancer* **2010**, *49*, 412–424. [CrossRef]

108. Prazeres, H.; Torres, J.; Rodrigues, F.; Pinto, M.; Pastoriza, M.C.; Gomes, D.; Cameselle-Teijeiro, J.; Vidal, A.; Martins, T.C.; Sobrinho-Simões, M.; et al. Chromosomal, Epigenetic and MicroRNA-Mediated Inactivation of LRP1B, a Modulator of the Extracellular Environment of Thyroid Cancer Cells. *Oncogene* **2011**, *30*, 1302–1317. [CrossRef]

109. Wang, Z.; Sun, P.; Gao, C.; Chen, J.; Li, J.; Chen, Z.; Xu, M.; Shao, J.; Zhang, Y.; Xie, J. Down-Regulation of LRP1B in Colon Cancer Promoted the Growth and Migration of Cancer Cells. *Exp. Cell Res.* **2017**, *357*, 1–8. [CrossRef]

110. Langbein, S.; Szakacs, O.; Wilhelm, M.; Sukosd, F.; Weber, S.; Jauch, A.; Beltran, A.L.; Alken, P.; Kalbe, T.; Kovacs, G. Alteration of the LRP1B Gene Region Is Associated with High Grade of Urothelial Cancer. *Lab. Invest.* **2002**, *82*, 639–643. [CrossRef]

111. Sonoda, I.; Imoto, I.; Inoue, J.; Shibata, T.; Shimada, Y.; Chinn, K.; Imamura, M.; Amagasa, T.; Gray, J.W.; Hirohishi, S.; et al. Frequent Silencing of Low Density Lipoprotein Receptor-Related Protein 1B (LRP1B) Expression by Genetic and Epigenetic Mechanisms in Esophageal Squamous Cell Carcinoma. *Cancer Res.* **2004**, *64*, 3741–3747. [CrossRef] [PubMed]

112. Rahmatpanah, F.B.; Carstens, S.; Guo, J.; Sjahputera, O.; Taylor, K.H.; Duff, D.; Shi, H.; Davis, J.W.; Hooshmand, S.I.; Chitman-Matsiga, R.; et al. Differential DNA Methylation Patterns of Small B-Cell Lymphoma Subclasses with Different Clinical Behavior. *Leukemia* **2006**, *20*, 1855–1862. [CrossRef] [PubMed]

113. Taylor, K.H.; Pena-Hernandez, K.E.; Davis, J.W.; Arthur, G.L.; Duff, D.J.; Shi, H.; Rahmatpanah, F.B.; Sjahputera, O.; Caldwell, C.W. Large-Scale CpG Methylation Analysis Identifies Novel Candidate Genes and Reveals Methylation Hotspots in Acute Lymphoblastic Leukemia. *Cancer Res.* **2007**, *67*, 2617–2625. [CrossRef] [PubMed]

114. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLeod, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma. *Nature* **2008**, *455*, 1099–1073. [CrossRef] [PubMed]

115. Liu, C.X.; Musco, S.; Lisistsina, N.M.; Yaklickin, S.Y.; Lisistsyn, N.A. Genomic Organization of a New Candidate Tumor Suppressor Gene, LRPIB. *Genomics* **2000**, *69*, 271–274. [CrossRef] [PubMed]

116. Marschang, P.; Brich, J.; Weeber, E.J.; Sweek, J.D.; Shelton, J.M.; Richardson, J.A.; Hammer, R.E.; Herz, J. Normal Development and Fertility of Knockout Mice Lacking the Tumor Suppressor Gene LRP1B Suggest Functional Compensation by LRPI. *Mol. Cell Biol.* **2004**, *24*, 3782–3793. [CrossRef]

117. Marzolo, M.P.; von Bernhardi, R.; Bu, G.; Inestrosa, N.C. Expression of Alpha(2)-Macroglobulin Receptor/Low Density Lipoprotein Receptor-Related Protein (LRP) in Rat Microglial Cells. *J. Neurosci. Res.* **2000**, *60*, 401–411. [CrossRef]

118. Cam, J.A.; Zerbinatti, C.V.; Knisely, J.M.; Hecimovic, S.; Li, Y.; Bu, G. The Low Density Lipoprotein Receptor-Related Protein 1B Retains Beta-Amyloid Precursor Protein at the Cell Surface and Reduces Amyloid-Beta Peptide Production. *J. Biol. Chem.* **2004**, *279*, 29639–29646. [CrossRef]

119. Arnaud, L.; Ballif, B.A.; Förster, E.; Cooper, J.A. Fyn Tyrosine Kinase Is a Critical Regulator of Disabled-1 during Brain Development. *Curr. Biol.* **2003**, *13*, 9–17. [CrossRef]

120. Kim, D.-H.; Iijima, H.; Goto, K.; Sakai, J.; Ishii, H.; Kim, H.-J.; Suzuki, H.; Kondo, H.; Saeki, S.; Yamamoto, T. Human Apolipoprotein E Receptor 2: A Novel Lipoprotein Receptor of the Low Density Lipoprotein Receptor Family Predominantly Expressed In Brain. *J. Biol. Chem.* **1996**, *271*, 8373–8380. [CrossRef]
121. Strom, T.B.; Tveten, K.; Holla, Ø.L.; Cameron, J.; Berge, K.E.; Leren, T.P. Characterization of Residues in the Cytoplasmic Domain of the LDL Receptor Required for Exit from the Endoplasmic Reticulum. *Biochim. Biophys. Res. Commun.* **2011**, *415*, 642–645. [CrossRef] [PubMed]

122. Ublit, M.T.; Temple, B.; Bencharit, S.; Kimple, A.J.; Siderovsky, D.P.; Johnson, G.L. Structural and Evolutionary Division of Phosphotyrosine Binding (PTB) Domains. *J. Mol. Biol.* **2005**, *345*, 1–20. [CrossRef] [PubMed]

123. Balmaceda, V.; Cuchillo-Ibañez, I.; Pujadas, L.; García-Ayllón, M-S.; Saura, C.A.; Nimpf, J.; Soriano, E.; Sáez-Valero, J. ApoER2 Processing by Presenilin-1 Modulates Reelin Expression. *FASEB J.* **2014**, *28*, 1543–1554. [CrossRef] [PubMed]

124. Teles, F.; Ma, Q.; Perez, F.M.; Notani, D.; Oh, S.; Li, W.; Comolotti, D.; Obgi, K.A.; Taylor, H.; Rosenfeld, M.G. LR8-Reelin-Regulated Neuronal Enhancer Signature Underlying Learning and Memory Formation. *Neuron* **2015**, *86*, 696–710. [CrossRef] [PubMed]

125. Sun, X.-M.; Soutar, A.K. Expression in Vitro of Alternatively Spliced Variants of the Messenger RNA for Human Apolipoprotein E Receptor-2 Identified in Human Tissues by Ribonuclease Protection Assays. *Eur. J. Biochem.* **1999**, *262*, 230–239. [CrossRef] [PubMed]

126. Clatworthy, A.E.; Stockinger, W.; Christie, R.H.; Schneider, W.J.; Nimpf, J.; Hyman, B.T.; Rebeck, G.W. Expression and Alternate Splicing of Apolipoprotein E Receptor 2 in Brain. *Neuroscience* **1999**, *90*, 903–911. [CrossRef] [PubMed]

127. Gallo, C.M.; Labadorf, A.T.; Ho, A.; Beffert, U. Single Molecule, Long-Read ApoER2 Sequencing Identifies Conserved and Species-Specific Splicing Patterns. *Genomics* **2022**, *114*, 110318. [CrossRef]

128. Hinrich, A.J.; Jodelka, F.M.; Chang, J.L.; Brutman, D.; Bruno, A.M.; Briggs, C.A.; James, B.D.; Stuttmann, G.E.; Bennett, D.A.; Miller, S.A.; et al. Therapeutic Correction of ApoER2 Splicing in Alzheimer’s Disease Mice Using Antisense Oligonucleotides. *EMBO Mol. Med.* **2016**, *8*, 328–345. [CrossRef] [PubMed]

129. Brandes, C.; Kahr, L.; Stockinger, W.; Hiesberger, T.; Schneider, W.J.; Nimpf, J. Alternative Splicing in the Ligand Binding Domain of Mouse ApoE Receptor-2 Produces Receptor Variants Binding Reelin but Not Alpha 2-Macroglobulin. *J. Biol. Chem.* **2001**, *276*, 22160–22169. [CrossRef]

130. Wasser, C.R.; Masiulis, I.; Durakoglugil, M.S.; Lane-Donovan, C.; Xian, X.; Beffert, U.; Agarwala, A.; Hammer, R.E.; Herz, J. Differential Splicing and Glycosylation of ApoER2 Alters Synaptic Plasticity and Fear Learning. *Sci. Signal.* **2014**, *7*, ra113. [CrossRef] [PubMed]

131. Beffert, U.; Nematollah Farsian, F.; Masiulis, I.; Hammer, R.E.; Yoon, S.O.; Giehl, K.M.; Herz, J. ApoE Receptor 2 Controls Neuronal Survival in the Adult Brain. *Curr. Biol.* **2008**, *16*, 2446–2452. [CrossRef] [PubMed]

132. Stockinger, W.; Hengstschläger-Ottnad, E.; Novak, S.; Matus, A.; Hüttlinger, M.; Bauer, J.; Lassmann, H.; Schneider, W.J.; Nimpf, J. The Low Density Lipoprotein Receptor Gene Family. Differential Expression of Two Alpha2-Macroglobulin Receptors in the Brain. *J. Biol. Chem.* **1998**, *273*, 32213–32221. [CrossRef]

133. Brandes, C.; Novak, S.; Stockinger, W.; Herz, J.; Schneider, W.J.; Nimpf, J. Avian and Murine LR8B and Human Apolipoprotein E Receptor 2: Differentially Spliced Products from Corresponding Genes. *Genomics* **1997**, *42*, 185–191. [CrossRef] [PubMed]

134. Myant, N.B. Reelin and Apolipoprotein E Receptor 2 in the Embryonic and Mature Brain: Effects of an Evolutionary Change in the ApoER2 Gene. *Proc. Biol. Sci.* **2010**, *277*, 345–351. [CrossRef]

135. Oumuro, K.C.; Gallo, C.M.; Scrandis, L.; Ho, A.; Beffert, U. Human APOER2 Isoforms Have Differential Cleavage Events and Synaptic Properties. *J. Neurosci.* **2002**, *42*, 4054–4068. [CrossRef] [PubMed]

136. Reddy, S.S.; Connor, T.E.; Weeber, E.J.; Rebeck, W. Similarities and Differences in Structure, Expression, and Functions of VLDLR and ApoER2. *Mol. Neurodegener.* **2011**, *6*, 30. [CrossRef] [PubMed]

137. Pasten, C.; Cerda, J.; Jausoro, I.; Court, F.A.; Cáceres, A.; Marzolo, M.P. ApoER2 and Reelin Are Expressed in Regenerating Peripheral Nerve and Regulate Schwann Cell Migration by Activating the Rac1 GEF Protein, Tiam1. *Mol. Cell Neurosci.* **2015**, *69*, 1–11. [CrossRef] [PubMed]

138. Waltmann, M.D.; Basford, J.E.; Konaniah, E.S.; Weintraub, N.L.; Hui, D.Y. Apolipoprotein E Receptor-2 Deficiency Enhances Macrophage Susceptibility to Lipid Accumulation and Cell Death to Augment Atherosclerotic Plaque Progression and Necrosis. *Biochim. Biophys. Acta* **2014**, *1842*, 1395–1405. [CrossRef]

139. Ulrich, V.; Konaniah, E.S.; Herz, J.; Gerard, R.D.; Jung, E.; Yuhanna, I.S.; Ahmed, M.; Hui, D.Y.; Mineo, C.; Shaul, P.W. Genetic Variants of ApoE and ApoER2 Differentially Modulate Endothelial Function. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 13493–13498. [CrossRef] [PubMed]

140. Huang, J.; Li, L.; Lian, J.; Schauer, S.; Vesely, P.W.; Kratky, D.; Hoefler, G.; Lehner, R. Tumor-Induced Hyperlipidemia Contributes to Tumor Growth. *Cell Rep.* **2016**, *15*, 336–348. [CrossRef]

141. Zheng, S.; Wei, Y.; Jiang, Y.; Hao, Y. LR8P Activates STAT3 to Induce PD-L1 Expression in Osteosarcoma. *Tumori* **2021**, *107*, 238–246. [CrossRef] [PubMed]

142. Maire, V.; Mahmood, F.; Rigail, G.; Ye, M.; Brisson, A.; Némati, F.; Gentien, D.; Tucker, G.C.; Roman-Roman, S.; Dubois, T. LR8P Is Overexpressed in Estrogen-Negative Breast Cancers and a Potential Target for These Tumors. *Cancer Med.* **2019**, *8*, 325–336. [CrossRef] [PubMed]

143. Dun, B.; Sharma, A.; Teng, Y.; Liu, H.; Purohit, S.; Xu, H.; Zeng, L.; She, J.-X. Mycophenolic Acid Inhibits Migration and Invasion of Gastric Cancer Cells via Multiple Molecular Pathways. *PLoS ONE* **2013**, *8*, e81702. [CrossRef] [PubMed]

144. Lu, J.; Ma, Y.; Zhao, Z. MiR-142 Suppresses Progression of Gastric Carcinoma via Directly Targeting LR8P. *Clin. Res. Hepatol. Gastroenterol.* **2021**, *45*, 101520. [CrossRef] [PubMed]
145. Cai, J.; Chen, J.; Wu, T.; Cheng, Z.; Tian, Y.; Pu, C.; Shi, W.; Suo, X.; Wu, X.; Zhang, K. Genome-Scale CRISPR Activation Screening Identifies a Role of LR8P in Sorafenib Resistance in Hepatocellular Carcinoma. Biochem. Biophys. Res. Commun. 2020, 526, 1170–1176. [CrossRef]

146. Pencheva, N.; Tran, H.; Buss, C.; Huh, D.; Drobnjak, M.; Busam, K.; Tavazoie, S.F. Convergent Multi-MiRNA Targeting of ApoE Drives LRPI/LR8P-Dependent Melanoma Metastasis and Angiogenesis. Cell 2012, 151, 1068–1082. [CrossRef] [PubMed]

147. Qiu, H.; Shen, X.; Chen, B.; Chen, T.; Feng, G.; Chen, S.; Feng, D.; Xu, Q. MiR-30b-5p Inhibits Cancer Progression and Enhances Cisplatin Sensitivity in Lung Cancer through Targeting LR8P. Apoptosis 2021, 26, 261–276. [CrossRef]

148. Fang, Z.; Zhong, M.; Zhou, L.; Le, Y.; Wang, H.; Fang, Z. Low-Density Lipoprotein Receptor-Related Protein 8 Facilitates the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Regulating the Wnt/β-Catenin Signaling Pathway. Bioengineered 2022, 13, 6807–6818. [CrossRef]

149. Arai, T.; Kojima, S.; Yamada, Y.; Sugawara, S.; Kato, M.; Yamazaki, K.; Naya, Y.; Ichikawa, T.; Seki, N. Pirin: A Potential Novel Therapeutic Target for Castration-resistant Prostate Cancer Regulated by MiR-455-5p. Mol. Oncol. 2019, 13, 322–337. [CrossRef]

150. Du, S.; Wang, H.; Cai, J.; Ren, R.; Zhang, W.; Wei, W.; Shen, X. Apolipoprotein E2 Modulates Cell Cycle Function to Promote Proliferation in Pancreatic Cancer Cells via Regulation of the C-Myc–P21 Waf1 Signalling Pathway. Biochem. Cell. Biol. 2020, 98, 191–202. [CrossRef]

151. Zhang, J.; Zhang, X.; Zhou, F.; van Dinther, M.; Ten Dijke, P. LRP8 Mediates Wnt/B/Akt and Glycogen Synthase Kinase 3β. J. Biol. Chem. 2002, 277, 2363–2372. [CrossRef] [PubMed]

152. Poirier, S.; Mayer, G.; Benjamnet, S.; Bergeron, E.; Marcinkiewicz, J.; Nassoury, N.; Mayer, H.; Nimpf, J.; Prat, A.; Seidah, N.G. The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. J. Biol. Chem. 2008, 283, 2363–2372. [CrossRef] [PubMed]

153. Huang, X.; Zhang, W.; Zhang, Z.; Shi, D.; Wu, F.; Zhong, B.; Shao, Z. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. J. Cancer 2019, 8, 2525–2531. [CrossRef] [PubMed]

154. Seidah, N.G. The PCSK9 Revolution and the Potential of PCSK9-Based Therapies to Reduce LDL-Cholesterol. Glob. Cardiol. Sci. Pract. 2017, 2017, e201702. [CrossRef] [PubMed]

155. Ruvolo, P.P. The Broken “Off” Switch in Cancer Signaling: PP2A as a Regulator of Tumorigenesis, Drug Resistance, and Immune Surveillance. BBA Clin. 2016, 6, 87–99. [CrossRef] [PubMed]

156. Komaravolu, R.K.; Waltmann, M.D.; Konaniah, E.; Jaeschke, A.; Hui, D.Y. ApoER2 (Apolipoprotein E Receptor-2) Deficiency Factors and Promotes Alzheimer’s Disease Progression: A Comparative Study Based on Han and She Populations in the Wenzhou Area. Brain Res. Bull. 2017, 132, 39–43. [CrossRef]

157. Bock, H.H.; Herz, J. Reelin Activates SRC Family Tyrosine Kinases in Neurons. Curr. Biol. 2003, 13, 18–26. [CrossRef]

158. Hoe, H.-S.; Wessner, D.; Beffert, U.; Becker, A.G.; Matsuoka, Y.; Rebeck, G.W. ApoER2 (Apolipoprotein E Receptor-2) Deficiency Accelerates Smooth Muscle Cell Senescence via Cytokinesis Impairment and Promotes Fibrotic Neoangioma After Vascular Injury. ATVVB 2019, 39, 2132–2144. [CrossRef] [PubMed]

159. Beffert, U.; Marfini, G.; Bock, H.H.; Reyna, H.; Brady, S.T.; Herz, J. Reelin-Mediated Signaling Locally Regulates Protein Kinase C-Induced Endocytosis of Amyloid-Beta Precursor Protein and Beta-Secretase, Leading to Amyloid-Beta Production. J. Neurosci. 2007, 27, 4052–4060. [CrossRef] [PubMed]

160. Meyer, D.; Liu, A.; Margolis, B. Interaction of C-Jun Amino-Terminal Kinase Interacting Protein-1 with P190 RhoGEF and Its Localization in Differentiated Neurons. J. Biol. Chem. 1999, 274, 35113–35118. [CrossRef] [PubMed]

161. Chen, Y. Reelin Modulates NMDA Receptor Activity in Cortical Neurons. J. Biol. Chem. 2002, 277, 49958–49964. [CrossRef] [PubMed]

162. Fan, Y.-Y.; Cai, Q.-L.; Gao, Z.-Y.; Lin, X.; Huang, Q.; Tang, W.; Liu, J.-H. APOE E4 Allele Elevates the Expressions of Inflammatory Factors and Promotes Alzheimer’s Disease Pathogenesis: A Comparative Study Based on Han and She Populations in the Wenzhou Area. Brain Res. Bull. 2017, 132, 39–43. [CrossRef]

163. Roche, K.W.; Standley, S.; McCallum, J.; Dune Ly, C.; Ehlers, M.D.; Wenthold, R.J. Molecular Determinants of NMDA Receptor Internalization. Nat. Neurosci. 2001, 4, 794–802. [CrossRef] [PubMed]

164. Cai, J.; Chen, J.; Wu, T.; Cheng, Z.; Tian, Y.; Pu, C.; Shi, W.; Suo, X.; Wu, X.; Zhang, K. Genome-Scale CRISPR Activation Signalling Pathway. BRCA Clin. 2016, 6, 87–99. [CrossRef] [PubMed]

165. Fuentealba, R.A.; Barriá, M.I.; Lee, J.; Cam, J.; Araya, C.; Escudero, C.A.; Inestrosa, N.C.; Bronfman, F.C.; Bu, G.; Marzolo, M.-P. ApoER2 Expression Increases Abeta Production While Decreasing Amyloid Precursor Protein (APP) Endocytosis: Possible Role in the Partitioning of APP into Lipid Rafts and in the Regulation of Gamma-Secretase Activity. Mol. Neurodegener. 2007, 2, 14. [CrossRef] [PubMed]

166. Fang, Z.; Zhong, M.; Zhou, L.; Le, Y.; Wang, H.; Fang, Z. Low-Density Lipoprotein Receptor-Related Protein 8 Facilitates the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Regulating the Wnt/β-Catenin Signaling Pathway. Bioengineered 2022, 13, 6807–6818. [CrossRef] [PubMed]

167. Ruvolo, P.P. The Broken “Off” Switch in Cancer Signaling: PP2A as a Regulator of Tumorigenesis, Drug Resistance, and Immune Surveillance. BBA Clin. 2016, 6, 87–99. [CrossRef] [PubMed]

168. Komaravolu, R.K.; Waltmann, M.D.; Konaniah, E.; Jaeschke, A.; Hui, D.Y. ApoER2 (Apolipoprotein E Receptor-2) Deficiency Accelerates Smooth Muscle Cell Senescence via Cytokinesis Impairment and Promotes Fibrotic Neoangioma After Vascular Injury. ATVVB 2019, 39, 2132–2144. [CrossRef] [PubMed]

169. He, X.; Cooley, K.; Chung, C.H.Y.; Dashi, N.; Tang, J. Apolipoprotein Receptor 2 and X11 Alpha/Beta Mediate Apolipoprotein E-Induced Endocytosis of Amyloid-Beta Precursor Protein and Beta-Secretase, Leading to Amyloid-Beta Production. J. Neurosci. 2007, 27, 4052–4060. [CrossRef] [PubMed]

170. Bock, H.H.; Herz, J. Reelin Activates SRC Family Tyrosine Kinases in Neurons. Curr. Biol. 2003, 13, 18–26. [CrossRef]

171. Beffert, U.; Morfini, G.; Bock, H.H.; Reyna, H.; Brady, S.T.; Herz, J. Reelin-Mediated Signaling Locally Regulates Protein Kinase B/Akt and Glycogen Synthase Kinase 3beta. J. Biol. Chem. 2002, 277, 49958–49964. [CrossRef] [PubMed]
196. Gao, S.; Jin, Y.; Hall, K.S.; Liang, C.; Unverzagt, F.W.; Ji, R.; Murrell, J.R.; Cao, J.; Shen, J.; Ma, F.; et al. Selenium Level and Cognitive Function in Rural Elderly Chinese. *Am. J. Epidemiol.* 2007, 165, 955–965. [CrossRef]

197. Berry, M.J.; Banu, L.; Harney, J.W.; Larsen, P.R. Functional Characterization of the Eukaryotic SECIS Elements Which Direct Selenocysteine Insertion at UGA Codons. *EMBO J.* 1993, 12, 3315–3322. [CrossRef]

198. Chen, J.; Berry, M.J. Selenium and Selenoproteins in the Brain and Brain Diseases. *J. Neurochem.* 2003, 86, 1–12. [CrossRef]

199. Burk, R.F.; Hill, K.E.; Olson, G.E.; Weeber, E.J.; Motley, A.K.; Winfrey, V.P.; Austin, L.M. Deletion of Apolipoprotein E Receptor-2 in Mice Lowers Brain Selenium and Causes Severe Neurological Dysfunction and Death When a Low-Selenium Diet Is Fed. *J. Neurosci.* 2007, 27, 6207–6211. [CrossRef]

200. Olson, G.E.; Winfrey, V.P.; NagDas, S.K.; Hill, K.E.; Burk, R.F. Apolipoprotein E Receptor-2 (ApoER2) Mediates Selenium Uptake from Selenoprotein P by the Mouse Testis. *J. Biol. Chem.* 2007, 282, 12290–12297. [CrossRef]

201. Medoro, A.; Bartollino, S.; Mignogna, D.; Passarella, D.; Porcile, C.; Pagano, A.; Florio, T.; Nizzari, M.; Guerra, G.; Di Marco, R.; et al. Complexity and Selectivity of γ-Secretase Cleavage on Multiple Substrates: Consequences in Alzheimer’s Disease and Cancer. *J. Alzheimers Dis.* 2018, 61, 1–15. [CrossRef] [PubMed]

202. Medoro, A.; Bartollino, S.; Mignogna, D.; Marziliano, N.; Porcile, C.; Nizzari, M.; Florio, T.; Pagano, A.; Raimo, G.; Intrieri, M.; et al. Proteases Upregulation in Sporadic Alzheimer’s Disease Brain. *J. Alzheimers Dis.* 2019, 68, 931–938. [CrossRef] [PubMed]